A Randomized, Double-Blind, Placebo-Controlled, Phase [ADDRESS_462301] 
Houston, TX [ZIP_CODE] 
Tel: ([PHONE_7619]  
Fax: ([PHONE_7620] [EMAIL_7092]
  
  
 
Co-PrincipaI Investigator 
Hilary Goldberg, MD, MPH 
Pulmonary and Critical Care Medicine Brigham and Women’s Hospi[INVESTIGATOR_307] [ADDRESS_462302] 
[LOCATION_011], MA [ZIP_CODE] 
Tel: 
[PHONE_7621]  
Fax: [PHONE_7622]  
[EMAIL_7093]  
 
Data Coordinating Center Director  
Cathie Spi[INVESTIGATOR_8614], D.Sc 
Department of Biostatistics 
School of Public Health II 
University of Michigan 1415 Washington Heights, Rm M4507 Ann Arbor, MI [ZIP_CODE] Tel: ([PHONE_7623] 
Fax: ([PHONE_7624] 
[EMAIL_7094]  
 
   
  
ii 
 Grant funding provided by:   [CONTACT_8229], Inc.  
[ADDRESS_462303] 
South San Francisco, CA [ZIP_CODE]  
 
Protocol Version Number:  v.8.0  
Protocol Version Date:  13OCT2020
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462304] OF ABBREVIATIONS  .............................................................................................................................. ..... 6 
STATEMENT OF COMPLIANCE  ......................................................................................................................... 8  
PROTOCOL SUMMARY  .............................................................................................................................. .......... 9  
SUMMARY SCHEMATIC OF STUDY DESIGN  ............................................................................................... 15  
1 KEY ROLES  .............................................................................................................................. .................... 16  
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ...................... 17  
2.1  Background Information  ............................................................................................................... 17  
2.1.1  RA-ILD  17  
2.1.2  Nonclinical Overview Supporting Use in RA-ILD  ....................................................... 18  
2.1.3  Summary of Findings from Human Clinical Studies  ................................................... 19  
[IP_ADDRESS]  Shionogi Phase 2 Study (SP2) (Azuma et al. 2005)  .................................................... [ADDRESS_462305] to Follow-Up  ............................................................................................... 32  
5.4  Premature Termination or Suspension of Study  .................................................................... 32  
5.5  Approval of nintedanib (OFEV) in the [LOCATION_002]  ............................................................. 33  
6 STUDY AGENT  .............................................................................................................................. .............. 33  
6.1  Study Agent(s) and Control Description  .................................................................................. [ADDRESS_462306] Storage & Stability  .............................................................................. 33  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 4 of 80 
 6.1.4  Dispensing of Study Treatment  ........................................................................ 33  
6.1.5  Pre-specified Dose Adjustment & Modifications  ............................................ 34  
6.1.6  Duration of Therapy  ........................................................................................... 36  
6.1.7  Missed Doses  ..................................................................................................... 36  
6.1.8  Interruption of Study Treatment  ....................................................................... 36  
6.1.9  Precautionary Measures  ................................................................................... 36  
6.2  Study agent Accountability Procedures  ................................................................................... 37  
7 STUDY PROCEDURES AND SCHEDULE  .............................................................................................. 37  
7.1  Study Procedures/Evaluations  ................................................................................................... 37  
7.1.1  Laboratory Assessments  .................................................................................. 38  
7.1.2  Clinical Assessments  ........................................................................................ 39  
7.2  Summary of Study Schedule and Assessments  .................................................................... 42  
7.2.1  Screening Period ................................................................................................ 42  
7.2.2  Assessments During Treatment  ....................................................................... 44  
7.3  Concomitant Medications & Treatments During the Study  ................................................. 47  
7.3.1  Concomitant Medications  ................................................................................. 47  
7.3.2  Treatment for Acute ILD Exacerbations  .......................................................... 48  
7.4  Prohibited Medications and Treatments During the Study  ................................................. 48  
8 ASSESSMENT OF SAFETY  ...................................................................................................................... 48  
8.1  Specification of Safety Parameters  ........................................................................................... 48  
8.2  Safety Data Exchange Agreement  ............................................................................................. 49  
8.2.1  Background  ........................................................................................................... 49  
8.2.2  Definitions  ........................................................................................................... 49  
8.2.3  Randomization Codes for Blinded Clinical Trials  ........................................... 50  
8.2.4  Reporting to Regulatory Authorities, Ethics Committees and Investigators 50 
8.2.5  Language  ............................................................................................................ 51  
8.2.6  Records  51 
8.3  AE and SAE Severity Grades and Relationship to Study Treatment  ................................ 52  
8.3.1  Adverse Event Reporting  .................................................................................. 52  
8.3.2  Serious Adverse Event Reporting  .................................................................... 52  
8.3.3  Unexpected Adverse Event Reporting  ............................................................ 53  
8.3.4  Reporting of Pregnancy  .................................................................................... 54  
8.4  Safety Oversight  ............................................................................................................................. 54 
9 CLINICAL MONITORING  ............................................................................................................................ 5 4 
10 STATISTICAL CONSIDERATIONS  .......................................................................................................... 55  
10.1  Randomization and Treatment Assignment  ............................................................................. 55  
10.2  Sample Size and Power Considerations  ................................................................................... 55  
10.2.1  Primary endpoint:  .............................................................................................. 55  
10.2.2  Secondary and exploratory endpoints:  ........................................................... 57  
10.3  Adverse Events  .............................................................................................................................. .. 57 
10.4  Statistical Analysis  .......................................................................................................................... 59  
10.4.1  Analysis Populations  ......................................................................................... 59  
10.4.2   Efficacy Analyses  .............................................................................................. 59  
10.4.3  Safety Analyses .................................................................................................. 60  
10.4.5  Administrative Reporting  .................................................................................. 60  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 5 of 80 
 10.4.6  Trial Monitoring and Interim Analyses  ............................................................ 60  
10.5  Measures to Minimize Bias  ........................................................................................................... 60  
10.5.1  Randomization and Blinding  ............................................................................ 60  
10.5.2  Unblinding of Treatment Assignment  .............................................................. 61  
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 61  
12 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................................................. 62  
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................... [ADDRESS_462307]  .............................................................................................................................. ...................... 70  
Appendix A  SCHEDULE OF STUDY ASSESSMENTS  ................................................................................................. 71  
Appendix B  TRAIL1 CAPSULE DOSING FLOWCHART  ............................................................................... 73  
Appendix C SAFETY REPORTING DEFINITIONS AND CONTACTS  ................................................. 74  
[COMPANY_002] Contacts ................................................................................................................ ........................................ 78  
BCM Contacts .................................................................................................................. ......................................... 79  
Appendix D TREATMENT ASSIGN MENT NOTIFICATION LETTER  ............................................................................ 80  
 
 
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462308] OF ABBREVIATIONS 
 
AE adverse event 
ALT/SGPT alanine aminotransferase/serum glutamic pyruvate transaminase 
ANCOVA analysis of covariance 
AST/SGOT aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
ATS American Thoracic Society 
BAL bronchoalveolar lavage 
bFGF basic fibroblast growth factor 
CI confidence interval 
CRF case report form 
D-12 Dyspnea 12 questionnaire 
DCC Data Coordinating Center 
DLCO carbon monoxide diffusing capacity 
% DL CO percent predicted carbon monoxide diffusing capacity 
DSMB Data Safety Monitoring Board 
ECG Electrocardiogram 
eCRF electronic case report form 
ERS European Respi[INVESTIGATOR_369221] ([LOCATION_002]) Food and Drug Administration 
FEV1 forced expi[INVESTIGATOR_369222] 
%FVC percent predicted forced vital capacity 
GGT gamma-glutamyl transferase 
GCP Good Clinical Practice 
HIV human immunodeficiency virus 
HRCT high-resolution computed tomography 
HRQOL Health Related Quality of Life 
IB Investigator’s Brochure 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
ILD Interstitial Lung Disease 
IND Investigational New Drug 
IPF idiopathic pulmonary 
IRB Institutional Review Board 
ITT intent-to-treat 
L liter 
LCQ Leicester Cough Questionnaire 
LDH lactic dehydrogenase 
L/min liters per minute 
MedDRA Medical Dictionary for Regulatory Activities  
m meter 
MAC Mortality Assessment Committee  
mg Milligram 
mg/d milligrams per day 
mL Milliliter 
mm Hg millimeters of mercury  
msec Millisecond 
NIH National Institutes of Health 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462309] in the heart's electrical 
cycle 
QTc heart-rate–corrected QT interval  
RA rheumatoid arthritis 
SAE serious adverse event  
SGRQ St. George’s Respi[INVESTIGATOR_369223]2 Shionogi Phase [ADDRESS_462310] upper limit of normal 
USP [LOCATION_002] Pharmacopeia  
UV-A ultraviolet A (radiation)    
wk Week 
Sponsor    Brigham and Women's Hospi[INVESTIGATOR_307], [LOCATION_011], MA 
Financial Support 
provided by [CONTACT_8229], Inc / [COMPANY_002] 
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 8 of 80 
 STATEMENT OF COMPLIANCE 
 
This trial will be conducted with Good Clinical Prac tice (GCP) and in accordance with the Code of 
Federal Regulations on the Protection of Human Subjects (21 CFR Part 50). The Principal 
Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without 
documented approval from the applicable Instit utional Review Boards (IRBs), except where 
necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in 
the conduct of this study have completed Human Subjects Protection Training.   
I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments.  
Principal Investigator: _________________________       
(Print/Type Name)  
Signed: _________________________ 
(Signature)       
  Date:                              
      (MM/DD/YYYY) 
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 9 of 80 
 PROTOCOL SUMMARY 
Title:  A Randomized, Double-Blind, Placebo- Controlled, Phase 2 Study of Safety, 
Tolerability and Efficacy of Pi[INVESTIGATOR_369224]écis:  A Phase 2, randomized, double blind, placebo controlled clinical trial 
designed to evaluate the efficacy and safety of administering pi[INVESTIGATOR_369225] 52 weeks to subjects with RA -ILD. Patients meeting the 
eligibility criteria for the study will be  randomized to receive either 
pi[INVESTIGATOR_7735] 2403 mg/d or placebo. Efficacy will be evaluated through 
interval testing of pulmonary function tests, patient reported outcomes, adverse events and survival.  Safety  will be assessed by [CONTACT_369347], 
serious adverse events, rates of acute exacerbation, hospi[INVESTIGATOR_138628]-
cause mortality.  
Objectives:  
 To assess the efficacy and safety of pi[INVESTIGATOR_7735] 2403 mg/day as compared 
to placebo in patients with RA -associated interstitial lung disease.   
To explore the role of peripheral bloo d biomarkers in predicting disease 
progression and survival in patients with RA-associated interstitial lung 
disease.  
To explore a spectrum of validated questionnaires to assess disease specific 
PROs including overall health, and perspectives on symptoms, performance 
and quality of life.  
Endpoints  Primary Endpoint:  
Incidence of the composite endpoi nt of decline from baseline in 
percent predicted FVC of 10% or greater or death during the study period.  
Pre-Specified Secondary Endpoints:   
1. Incidence of the composite endpoint of decline from baseline in 
percent predicted FVC of 10% or greater during the study period 
2. Frequency of progressive disease as defined by [CONTACT_141374]: Relative 
decline from baseline in percent predicted FVC of ≥10%, or relative 
change from baseline in percent predicted FVC ≥ 5% and < 10%, and 
≥15% relative DL CO (Khanna, Mittoo et al. 2015 ) 
3. Change from baseline to end of study in absolute value of FVC 
4. Change from baseline to end of study of percent predicted FVC 
5. Slope  of  percent predicted FVC over study period 
6. Slope of absolute FVC over study period 
7. Time to decline of 10% or greater in percent predicted FVC or death 
over study  period 
8. Proportion of participants with all-cause mortality 
9. Proportion of participants with all-cause hospi[INVESTIGATOR_369226]1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 10 of 80 
 10. Proportion of participants with ho spi[INVESTIGATOR_369227] 
11. Number of respi[INVESTIGATOR_369228] 
12. Proportion of participants with  and number of treatment-em ergent 
AEs 
13. Proportion of participants with  and number of treatment-em ergent 
serious adverse events (SAEs) 
14. Proportion of participants wi th and number of treatment-
emergent/treatment-related AEs 
15. Proportion of participants wi th and number of treatment-
emergent/treatment-related SAEs 
16. Proportion of participants with and number of AEs leading to early 
discontinuation of study treatment 
17. Proportion of participants with  and number of treatment-em ergent 
death or transplant 
18. Proportion of participants with  and number of treatment-em ergent 
RA-ILD-related mortality 
19. Change from Baseline to end of st udy in dyspnea, as measured by 
[CONTACT_369348] 12 questionnaire 
Exploratory:  
1. Change from Baseline to end of study in Disease Activity Score 
(DAS) and RAPID3 score (RA disease activity score) 
2. Change from Baseline to end of study in Routine Assessment of 
Patient Index Data 3 (RAPID3) sco re (RA disease activity score) 
3. Change from Baseline to end of study in Erythrocyte Sedimentation 
Rate (ESR)  
4. Change from Baseline to end of st udy in C-Reactive Protein (CRP)  
5. Candidate biomarker expression in the peripheral blood of patients 
with RA-ILD over the study period of treatment and the study 
follow-up period 
6. Changes from Baseline to end of study in HRCT parameters 
evaluated by [CONTACT_369349] 
7. Changes from Baseline to Week 13, 26, [ADDRESS_462311]. 
George’s Respi[INVESTIGATOR_6015] (SGRQ) 
8. Changes from Baseline to Week 13, 26 and 39 in Dyspnea 12 
questionnaire 
9. Changes from Baseline to Week 13, 26, 39 and 52 in Leicester 
Cough Questionnaire (LCQ) 
10. Changes from Baseline to Week 13, 26, 39 and 52 in the Patient 
global assessment 
11. Changes from Baseline to Week 13, 26, 39 and 52 in the Health 
assessment questionnaire 
Population:  Approximately 270 randomized participants from recruitment sites in the 
[LOCATION_002] , Canada, the [LOCATION_008] and Australia, including both 
male and female patients aged 18 -85 years, diagnosed with RA ( according 
to revised 2010 ACR/EULAR criteria) and ILD (supported by [CONTACT_369350]1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462312]), without evidence or suspi[INVESTIGATOR_369229]. They must also meet 
all other inclusion and exclusio n criteria as detailed below.  
Phase:  Phase II  
Number of Sites 
enrolling participants: approximately 33  
Description of Study 
Agents:  Study treatment is defined as either pi[INVESTIGATOR_7735] 2403 mg/d or placebo 
equivalent administered in divided doses three times per day (TID).   
Study treatment should be titrated over  14 days, as tolerated, to the full 
dose of 9 capsules per day (three capsule s TID), as follows: 
• Days 1–7:  one capsule TID 
• Days 8–14:  two capsules TID 
• Days 15-21:  three capsules TI D (maximum of 9 capsules daily) 
Participants will remain on a stable maintenance dose for the duration of 
the study period (Day 22 to Week 52) un less the dose is reduced to manage 
an AE . 
Gene ntech will supply all study medications (pi[INVESTIGATOR_369230]). There will be [ADDRESS_462313], white gelatin capsules that are visually indistinguishable. 
Study Duration:  Approximately 4 years total study duration, sub-divided into the following 
components:  
- 30 month enrollment period  
- 12 month randomized, double-blind treatment period per patient  
- 1 month follow-up period after completion of drug therapy  
Participant Duration:  Approximately 15 months:  
- screening = 1-2 months 
- treatment period = 12 months  
- follow-up after completion of study treatment = 1 month  
Inclusion Criteria:  1. Age 18 through 85 years, inclusive, at Screening 
2. Probable or definite diagnosis of  RA according to revised 2010 
ACR/EULAR criteria, without evidence or suspi[INVESTIGATOR_369231].  
3. Diagnosis of ILD  
a. 
supported by [CONTACT_369351], and when available surgical 
lung biopsy (SLB), prior to Screening, and 
b. presence of fibrotic abnormality affecting more than 10% of the 
lung parenchyma, with or without traction bronchiectasis or 
honeycombing, on Screening and confirmed by [CONTACT_369352]1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 12 of 80 
 4. No features supporting an alternative diagnosis on transbronchial 
biopsy, or SLB, if performed prior to Screening 
5. Attainment of the following centra lized spi[INVESTIGATOR_96840] (based on 
local spi[INVESTIGATOR_369232]): 
a. percent predicted FVC ≥ 40% at Screening 
b. change in pre-bronchodilator FVC (measured in liters) between 
Screening (Visit 1) and Baseline (Visit 2) must be a <10% relative 
difference, calculated as: 100% * [absolute value (Screening FVC – 
Baseline FVC) / Screening FVC]       
c. percent predicted DL CO or TLCO ≥ 25% at Screening 
d. Screening (Visit 1) pre-bronchodilator(BD) and Post-BD 
spi[INVESTIGATOR_369233] a central 
reviewer 
e. Baseline (Visit 2) Pre-BD spi[INVESTIGATOR_369234] a site Inve stigator or the central reviewer 
6.      Able to understand and si gn a written informed consent form 
7.      For women of childbearing potential:  agreement to remain abstinent 
(refrain from heterosexual intercourse) or use two adequate 
methods of contraception, includi ng at least one method with a 
failure rate of <1% per year, during the [ADDRESS_462314] dose of study drug.  
a. A woman is considered to be of ch ildbearing potential if she is 
postmenarcheal, has not reached a postmenopausal state ( ≥ 
12 continuous months of amenorrhea with no identified cause 
other than menopause), and has not undergone surgical 
sterilization (removal of ovaries and/or uterus). 
b. Examples of contraceptive methods with a failure rate of <1% 
per 
year include bilateral tubal ligation, male sterilization, established 
and proper use of hormonal contraceptives that inhibit ovulation, 
hormone- releasing intrauterine devices, and copper intrauterine 
devices. 
c. The reliability of sexual abstinence should be evaluated in relation 
to the duration of the clinical trial and the preferred and usual 
lifestyle of the patient.  Period ic abstinence (e.g., calendar, 
ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. 
8.        For men who are not surg ically sterile: agreement to remain 
abstinent (refrain from hetero sexual intercourse) or use 
contraceptive measures, and agree ment to refrain from donating 
sperm, as defined below:  
a. With female partners of childbe aring potential, men must remain 
abstinent or use a condom plus an additional contraceptive 
method that together result in a failure rate of  < 1% per year 
during the treatment period and fo r at least [ADDRESS_462315] refrain from donating sperm during this same period. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 13 of 80 
 Exclusion Criteria:  1. Not a suitable candidate for enrollm ent or unlikely to comply with 
the requirements of this study, in  the opi[INVESTIGATOR_871] 
2. Cigarette smoking or vapi[INVESTIGATOR_233488] 3 months of Screening or 
unwilling to avoid tobacco pro ducts throughout the study 
3. History of clinically significant environmental exposure known to 
cause pulmonary fibrosis (PF), including but not limited to drugs 
(such as amiodarone), asbestos, beryllium, radiation, and domestic 
birds 
4. Concurrent presence of the following conditions: 
a.  Other interstitial lung disease, related to but not limited to    
radiation, drug toxicity, sarcoidosis, hypersensitivity pneumonitis, or bronchiolitis obliterans organizing pneumonia 
b.  Medical history including Human Immunodeficiency Virus (HIV)
 
   c.  Medical history of viral hepatitis (positive Hep A antibody in the 
      absence of elevated live r enzymes is not an exclusion) 
5. Concurrent presence of other pleuropulmonary manifestations of 
RA, including but not limited to rh eumatoid nodular disease of the 
lung, pleuritis/pleural thickening , and obliterative bronchiolitis 
6. Post-bronchodilator FEV1/FVC  <0.65 at Screening 
7. Presence of pleural effusion occupying more than 20% of the 
hemithorax on Screening HRCT 
8. Clinical diagnosis of a second connective tissue disease or overlap 
syndrome (including but not limited to scleroderma, Sjogren’s 
polymyositis/dermatomyositis, systemic lupus erythematosus but 
excluding Raynaud’s phenomena) 
9. Coexistent clinically significant COPD/emphysema or asthma in the 
opi[INVESTIGATOR_369235] 
10. Clinical evidence of active infection, including but not limited to 
bronchitis, pneumonia, sinusitis, urinary tract infection, or cellu litis.  
The infection should be resolved per PI [INVESTIGATOR_369236].  Any use of antibiotics must be completed 2 weeks prior to the screening visit. Note that prophylactic antibiotics are not contraindicated or exclusionary 
11. Any history of malignancy diagnosed within 5 years of screening, 
other than basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or low grade cervical carcinoma, and/or 
low 
grade prostate cancer.  
Criteria for low grade prostate cancer: 
x Patients with suspi[INVESTIGATOR_369237]/or 
DRE should have been evaluated by [CONTACT_369353] 
x Patients with NCCN very low risk prostate cancer (· T1c and 
Grade Group 1 (Gleason 6) and PSA <10 ng/mL and Fewer than 3 
prostate biopsy fragments/cores positive, ≤50% cancer in each 
fragment/coreg and · PSA density <0.15 ng/mL/g) can be 
monitored without intervention and enrolled in study 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 14 of 80 
 x Patients with NCCN low risk prostate cancer can be  monitored 
on a case by [CONTACT_413] (T1-T2a and Grade Group 1 (Gleason 6) 
and · PSA <10 ng/mL) and enrolled in study. 
x All other patients should be excluded. 
12. History of LFT abnormalities as outlined below, or imaging, 
laboratory or other clinical info rmation suggesting liver dysfunction, 
advanced liver disease or cirrhosis.  Evidence of hepatic impairment 
that in the opi[INVESTIGATOR_369238].  
              Any of the following liver function abnormalities: 
a.Total bilirubin above the upper limit of normal (ULN), excluding 
patients with Gilbert’s syndrome; 
b.Aspartate or alanine aminotransferase (AST/SGOT or AST/SGPT) > 
[ADDRESS_462316]; 
c. Alkaline phosphatase > 2.[ADDRESS_462317] criteria above specified limits: 
a. eGFR < 30 mL/min/1.73m2 
b. Electrocardiogram (ECG) with a QTc interval >500 msec at 
Screening 
19. Prior use of pi[INVESTIGATOR_369239] 
20. Use of any of the following therapi[INVESTIGATOR_6523] 28 days before 
Screening  and during participation in the study: 
a. Investigational therapy, defined as any drug that has not been 
approved for marketing for any indication in the country of the 
participating site 
              b. Potent inhibitors of CYP1A2  (e.g. fluvoxamine, enoxacin) , 
              c. Potent inducers of CYP1A2 
              d. Sildenafil (daily use). Note: in termittent use for erectile      
dysfunction is allowed 
21. Introduction and/or modification of dose of corticosteroids or any 
cytotoxic, immunosuppressive, or cy tokine modulating or receptor 
antagonist agent for the management of pulmonary manifestations 
of RA, within 3 months of screening, is an exclusion criterion, with 
the exception of dose modification of  systemic corticosteroids that 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 15 of 80 
 are maintained at or below 20 mg prednisone daily or the 
equivalent.  
 
However, i ntroduction and/or modification of dose of corticosteroids 
or any cytotoxic, immunosuppressive, or cytokine modulating or 
receptor antagonist agent for the management of extrapulmonary  
manifestations of RA is not  an exclusion criterion for enrollment. 
  
22.  Any use of an approved anti-fibrotic medication within 28 days of 
screening. 
 
 
SUMMARY SCHEMATIC OF STUDY DESIGN 
Visit 1 (week -8 to week 0) SCREENING 
•Obtain informed consent 
•Screen potential subjects by [CONTACT_369354] 
•H&P, labs, ECG, HRCT, Spi[INVESTIGATOR_038], DLCO, biomarkers (see study assessment calendar for details) 
 
Visit 2 (week 0) ELIGIBILITY/RANDOMIZATION 
•H&P, labs, PROs, joint count, Spi[INVESTIGATOR_038], biom arkers (see study assessment calendar for details) 
•Confirm eligibility and randomize patient 
•Treatment Group 1 (n=135) 
•Placebo (n=135) 
•Dispense study drug 
•AE assessment 
 
Visit 3 (week 1) TELEPHONE ASSESSMENT 
•Vital status, dosing compliance 
•Concomitant medication assessment 
•AE assessment 
 
Visit 4 (week 2) TELEPHONE ASSESSMENT 
•Vital status, dosing compliance •Concomitant medication assessment 
•AE assessment 
 
Visit 5 (week 4) and Visit 6 (week 8) PROTOCOL VISIT 
•H&P, labs, biomarkers (week 4 only), ECG (week 4 only) 
•Review drug compliance •AE assessment 
 
Visit 7 (week 13), Visit 9 (week 26) and Visit 10 (week 39) PROTOCOL VISIT / DISPENSE DRUG 
•H&P, labs, biomarkers, PROs, ECG, Spi[INVESTIGATOR_038] 
•Dispense supply of study drug 
•AE assessment 
 
Visit 8 (week 19) LAB ASSESSMENT 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 16 of 80 
 •Liver function testing 
    •Concomitant medication assessment 
•AE assessment 
 
Visit 11 (week 52) END OF TREATMENT 
•H&P, labs, biomarkers, PROs , joint count, Spi[INVESTIGATOR_038], DLCO, ECG, HRCT 
    •Collect diary and unused study drug 
•AE assessment 
 
Visit 12 END OF STUDY PHONE CALL  ([ADDRESS_462318] DOSE OF STUDY DRUG) 
x Vital status and AE assessment 
 
PRE-RESTART VISIT  
•H&P, labs, ECG •AE assessment 
• Dispense supply of study drug, if required 
•Review drug compliance, dispense new diary, if required 
 
UNSCHEDULED VISIT  
x H&P, AE assessment 
x remaining elements of the visit are up to the discretion of the investigator. 
 
EARLY TERMINATION VISIT  
•H&P, labs, biomarkers, PROs , joint count ,Spi[INVESTIGATOR_038], DLCO, ECG, HRCT (see study assessment calendar for 
details) 
•Collect diary and unused study drug 
•AE assessment 
 
 
[ADDRESS_462319] Houston, TX [ZIP_CODE] 
Tel: ([PHONE_7619] 
Fax: ([PHONE_7620] 
[EMAIL_7092]  
Brigham and Women’s, [LOCATION_011], MA Co-PrincipaI Investigator 
Hilary Goldberg, MD, MPH 
Pulmonary and Critical Care Medicine Brigham and Women’s Hospi[INVESTIGATOR_307] 
[ADDRESS_462320] 
[LOCATION_011], MA [ZIP_CODE] 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 17 of 80 
 Tel: [PHONE_7621] 
Fax: [PHONE_7622] 
[EMAIL_7093]  
 Director, HRCT Image Analysis Core 
      David Lynch, MD 
 Director, Research Pharmacy Core 
      Josh Solomon, MD  
 Director, Pathology Review Team 
       Bobby [CONTACT_369355], PFT Core 
      Sonye Danoff, MD, PhD  
Data Coordinating Center 
University of Michigan  
Ann Arbor, MI  Director of Data Coordinating Center  
Cathie Spi[INVESTIGATOR_8614], D.Sc. 
Associate Research Professor of Biostatistics  Director, Statistical Analysis of Biomedical and Educational Research (SABER) Unit  School of Public Health  
University of Michigan 
1415 Washington Heights, Rm M4507 Ann Arbor, MI [ZIP_CODE] Tel: ([PHONE_7623] Fax: ([PHONE_7624] 
[EMAIL_7094]  
 
2 INTRODUCTION: BACKGROUND INFORM ATION AND SCIENTIFIC RATIONALE  
 
2.1  BACKGROUND INFORMATION  
 
2.1.1  RA-ILD  
RA is a chronic inflammatory dise ase that leads to joint damage, deformity, and a high rate of 
disability and unemployment (Isomaki, Mutru et al . 1975; Allebeck, Ahlbom et al. 1981; Pi[INVESTIGATOR_35807], 
Callahan et al. 1984; Wolfe, Mitchell et al. 1994; Yelin 1996; Wallberg-Jonsson, Ohman et al. 1997; 
Gabriel, Crowson et al. 1999; Guedes, Dumont-Fischer et al. 1999).  The prevalence of RA is 1-2%, with 
a 2-fold higher prevalence in women than men (H ochberg and Spector 1990; Doran, Pond et al. 2002).  
The economic burden of RA is high: direct and indi rect costs in the U.S. a re estimated at more than 30 
billion USD per year, respectively (Lubeck 1994).  Furthe rmore, the lifespan of RA patients is shortened 
by [CONTACT_3450] 10 years (Isomaki, Mutru et al. 197 5; Allebeck, Ahlbom et al. 1981; Pi[INVESTIGATOR_35807], Callahan 
et al. 1984; Wolfe, Mitchell et al. 1994; Yelin 1996; Wallberg-Jonsson, Ohman et al. 1997; Gabriel, 
Crowson et al. 1999; Guedes, Dumont-Fischer et al. 1999; Doran, Pond et al. 2002), and standardized 
mortality ratios for RA range from 1. 28 to 3.0 (Wolfe, Mitchell et al. 1994).  
ILD is a common pulmonary manifestation of RA (Kim  2006).  Estimates of the prevalence of ILD vary 
based on the ascertainment technique: pulmonary func tion testing (PFT), chest CT or lung biopsy. 
High-resolution chest CT is more sensitive than PFTs for identifying ILD and is abnormal in 19% of an 
unselected RA population (Dawson, Fewins et al. 2001) and up to 80% of RA patients with respi[INVESTIGATOR_037] (McDonagh, Greaves et al. 1994).  Th e most common radiographic findings on CT are 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 18 of 80 
 reticular changes including honeycombing (HC), ground glass opacities (GGO), traction bronchiectasis 
and consolidation (Cortet, Perez et al. 1997; Dawson, Fe wins et al. 2001).  Pathologic evaluation on 
lung biopsy is the most sensitive assessment; ILD wa s present in 80% of subjects from one case series 
in which RA patients, not selected for respi[INVESTIGATOR_369240], underwent surgical lung biopsies 
(Cervantes-Perez, Toro-Perez et al. 1980).  Among RA patients biopsied for a diagnosis of ILD, usual 
interstitial pneumonia (UIP) is the most common hist opathologic pattern seen (Lamblin, Bergoin et al. 
2001), the same pattern seen in pati ents with idiopathic pulmonary fibrosis. This is in contrast to most 
other forms of collagen vascular associated-ILD (CVD-ILD), in which non-specific interstitial 
pneumonitis (NSIP) predominates (Lamblin, Bergoin et  al. 2001).  This may account, in part, for the 
poorer prognosis associated with RA-ILD in comparis on with other CVD-ILD (Lamblin, Bergoin et al. 
2001).  
Most patients develop articular symptoms of RA before lung involvement manifests, although these 
may occur simultaneously (Lee, Kim et al. 2005) or  ILD may begin even before articular symptoms are 
present (Sato, Fujita et al. 2006).  The initial symptoms of RA-ILD, when present, are often non-
specific, and include dyspnea with exertion and dry cough (Kim 2006). Moreover, the symptoms of RA-ILD overlap with symptoms of other comorbid conditio ns occurring in RA, such as cardiac disease, and 
may be missed in early stages due to reduced physi cal activity masking dyspne a.  Interstitial lung 
disease develops in a progressive fashion presumably following an unrecognized initial insult in a 
susceptible host.  The pathogenesis of the earliest  phase of ILD in humans remains unknown.  A study 
which evaluated radiographic progression in a small cohort of RA patients indicated that even in 
patients with asymptomatic diseas e, radiographic progression by [CONTACT_369356] (ER) 
occurs in nearly 60% of patients over an 18 month period (Gochuico, Avila et al. 2008). 
Interstitial lung disease (ILD) is a significant contribu tor to excess mortality in patients with RA. . A long 
term, population based cohort study of ILD in RA revealed that patients with RA related ILD are at 
nearly3-fold increased risk of premature death compa red to patients without this complication, a risk 
even higher than that for premature mortality due to  cardiovascular disease (Bongartz et al, 2010.) A 
further longitudinal cohort study showed that RA-ILD is responsible for a significant increase in 
mortality (Young, Koduri et al. 2007). A recent nation al study of mortality in RA showed that nearly 
10% of the deaths in RA are attributable to ILD (Olson , Swigris et al.) consistent with a prior, single 
center study (Suzuki, Ohosone et al. 1994). Currently available treatment for RA has achieved a great 
improvement in the control of articular disease as  measured by [CONTACT_369357] (van Vollenhoven 2009). Unfortunately, these benefits have not extended to RA-
associated lung disease.   
2.1.2  Nonclinical Overview Supporting Use in RA-ILD  
The mechanism of action of pi[INVESTIGATOR_369241]-inflammatory and 
antifibrotic. Pi[INVESTIGATOR_369242]-inflammatory cytokines and reduces 
the accumulation of inflammatory cells in response to various stimuli (Pi[INVESTIGATOR_369243]’s 
Brochure, Edition 11, [ADDRESS_462321] Characteristics, 24 April 2017). Pi[INVESTIGATOR_369244], production of fibrosis-associated proteins and 
cytokines, and the increased biosynthesis and accu mulation of extracellular matrix in response to 
cytokine growth factors such as tr ansforming growth factor-beta (TGF- β) and platelet-derived growth 
factor (PDGF). 
In rat, hamster, and mouse models of bleomycin-in duced lung fibrosis, prophylactic administration of 
pi[INVESTIGATOR_369245]. Pi[INVESTIGATOR_369246]1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462322] growth factor (bFGF), and various pro-inflammatory 
cytokines. 
Thus, both in vitro and in vivo nonclinical studies ha ve provided evidence of reductions in fibroblast 
proliferation and collagen synthesis, decreased cellular and histologic markers of lung fibrosis, and 
reduced perturbations in lung function in animal mo dels of fibrosis induction following administration 
of pi[INVESTIGATOR_7735]. 
2.1.3  Summary of Findings from  Human Clinical Studies  
A total of 15 controlled and uncontrolled clinical stud ies in healthy subjects and patients with IPF or 
pulmonary fibrosis (PF) have been conducted by [CONTACT_369358] (the original developer of pi[INVESTIGATOR_7735]), 
Shionogi, or InterMune. More than [ADDRESS_462323] 
been reported in the literature, with generally favo rable results (Nagai et al. 2002; Raghu et al. 1999; 
Gahl et al. 2002). InterMune has conducted mult iple Phase 1 studies to assess the clinical 
pharmacology and safety of pi[INVESTIGATOR_369247] o long-term, uncontrolled safety studies that are 
currently ongoing (PI[INVESTIGATOR_16335] -002 and PI[INVESTIGATOR_16335] -012). 
The double-blind, placebo-controlled Phase 2 study conducted by [CONTACT_369359] (SP2) served as 
the initial proof-of-concept study, suggesting a benefit of pi[INVESTIGATOR_16330]. Three Phase 
3 studies were subsequently executed independe ntly to confirm these findings, one in Japan 
(Shionogi-sponsored Phase 3 study [SP3], initiated in July 2004) and two in North America, Europe, 
and Australia (InterMune-sponsored PI[INVESTIGATOR_16335]-004 and PI [INVESTIGATOR_16335]-006, initiated in July 2006 and April 2006, 
respectively). Results from SP3, which was ongoing at the start of PI[INVESTIGATOR_16335]-004 and PI[INVESTIGATOR_16335]-006, formed the 
basis for approval of pi[INVESTIGATOR_7735] (Pi[INVESTIGATOR_369248]®) in Japan in October 2008. Efficacy results from these four 
trials are summarized below. 
[IP_ADDRESS]  Shionogi Phase 2 Study (SP2) (Azuma et al. 2005)  
SP2 was a multicenter, randomized, double-blind, plac ebo-controlled trial of pi[INVESTIGATOR_369249] a confirmed diagnosis of IPF conducted from 09 November 2000 to 30 September 2002 (Azuma 
et al. 2005). A total of 109 patients in Japan were ra ndomized in a 2:1 ratio to receive oral pi[INVESTIGATOR_7735] 
(1800 mg/d) or placebo for [ADDRESS_462324] a pi[INVESTIGATOR_369250] (mean area-above-the-curv e for oxygen saturation by [CONTACT_406] [SpO2] 
during the 6-minute steady state exercise test [6ME T], 8.12 vs. 8.23; p = 0.093). In secondary analyses, 
patients receiving pi[INVESTIGATOR_260349] a reduced mean de cline from Baseline in vital capacity (VC) (-0.03 L 
vs. -0.13 L; p = 0.037) and a lower rate of acute exacerbations of IPF (1.4% vs. 14.3%; p = 0.014). 
[IP_ADDRESS]  Shionogi Phase 3 Study (SP3) (Taniguchi et al. 2010)  
SP3 was a multicenter, randomized, double-blind, placebo-controlled, Phase [ADDRESS_462325] 2006 (Taniguchi  et al. 2010).  A tota l of 275 IPF patients 
from 73 sites were randomized 2:2:1 to receive pi[INVESTIGATOR_369251] 1800 mg/d, placebo, or pi[INVESTIGATOR_7735] 1200 
mg/d for 52 weeks. Sixty-six percent of patients completed the study.  SP3 demonstrated a significant 
benefit of pi[INVESTIGATOR_7735] 1800 mg/d compared with plac ebo on the primary outcome variable of change 
from Baseline in VC at Week 52 (- 90 mL vs. -160 mL; absolute di fference 70 mL; relative difference 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 20 of 80 
 43.8%; p = 0.042, analysis of covariance [ANCOVA]) . There was also a reduced mean decline in %VC at 
Week 52 in the pi[INVESTIGATOR_7735] 1800 mg/d group (- 2.91% vs. -5.13%; p = 0.044, ANCOVA). 
Progression-free survival (PFS), one of two key pre -specified secondary endpoints, was prolonged in 
pi[INVESTIGATOR_7735] 1800 mg/d-treated patients relative to  placebo (hazard ratio [HR] 0.45; 95% confidence 
interval [CI] 0.11–0.79; p = 0.028, log-rank test).  In the pi[INVESTIGATOR_7735] 1200 mg/d  treatment group, there 
was also a reduced mean decline in VC compared  with placebo (-80 mL vs. -160 mL; p = 0.039, 
ANCOVA), without evidence of a dose response compared with pi[INVESTIGATOR_7735] 1800 mg/d. 
[IP_ADDRESS]  InterMune PI[INVESTIGATOR_16335]-004  
In PI[INVESTIGATOR_16335]-004, a multinational, Phase 3, double-blind,  placebo-controlled study, 435 patients with IPF 
were randomized 2:2:1 to receive pi[INVESTIGATOR_7735] 2403 mg/d  (n = 174), placebo (n = 174), or pi[INVESTIGATOR_7735] 
1197 mg/d (n = 87). Study treatment lasted from  randomization until approximately [ADDRESS_462326] patients (84%) completed the study. 
In the primary efficacy analysis, treatment with pi[INVESTIGATOR_7735] 2403 mg/d resulted in a statistically 
significant reduction in the mean decline from Ba seline in percent predicted forced vital capacity 
(%FVC) at Week 72 compared with placebo (-8.0% vs. -12.4%; absolute difference 4.4%; relative 
difference 35.3%; p = 0.001, rank ANCOVA), as well  as across all study ti me points using a repeated 
measures analysis (p < 0.001). In an analysis of PFS, there was a 36% reduced risk of death or disease 
progression with pi[INVESTIGATOR_7735] 2403 mg/d treatment at Week 72 relative to placebo (HR 0.64; 95% CI 
0.44– 0.95; p = 0.023, log-rank test), and a much lower proportion of patients with a decline of ≥10% 
in %FVC at Week 72 in the pi[INVESTIGATOR_7735] 2403 mg/d group (20.1% vs. 34.5%). There was no discernible 
effect of pi[INVESTIGATOR_369252]. 
There was a 39% relative reduction in the risk of de ath in the pi[INVESTIGATOR_7735] 2403 mg/d group compared 
with placebo (HR 0.61; 95% CI 0.28–1.29; p = 0.191). In the analyses of on-treatment mortality, both 
the incidence of on-treatment all-cause deaths (i.e.,  deaths occurring between time of randomization 
and [ADDRESS_462327] dose of study treatment an d that of  IPF-related deaths was lower in the 
pi[INVESTIGATOR_7735] 2403 mg/d group than in the plac ebo group (10 vs. 14 deaths and 5 vs. 11 deaths, 
respectively).  Evidence of a dose response was observed with pi[INVESTIGATOR_7735] 1197 mg/d relative to 
pi[INVESTIGATOR_7735] 2403 mg/d in the analysis of the primary efficacy outcome and several secondary 
outcome variables. 
[IP_ADDRESS]  InterMune PI[INVESTIGATOR_16335]-[ADDRESS_462328] all major design features; however, PI[INVESTIGATOR_16335]-006 
included two rather than three treatment groups. A to tal of 344 patients were randomized to receive 
pi[INVESTIGATOR_7735] 2403 mg/d (171 patients) or placebo( 173 patients). Most patients (83%) completed the 
study. 
The primary efficacy analysis did not reach statistical  significance (mean change from Baseline in %FVC 
at Week 72, -9.0% vs. -9.6%; p = 0.501, rank ANCO VA); however, there was evidence of a treatment 
effect of pi[INVESTIGATOR_7735] 2403 mg/d at multiple ear lier time points (p < 0.001 at Week 24, p = 0.011 at 
Week 36, and p = 0.005 at Week 48). In addition, a re peated measures analysis with averaging across 
all study time points showed a reduced decline from Baseline in %FVC in pi[INVESTIGATOR_7735] 2403 mg/d 
patients overall (p = 0.007). Also, there was evidence  of an effect of pi[INVESTIGATOR_7735] 2403 mg/d compared 
with placebo in the change from Baseline in 6-mi nute walk test (6MWT) distance at Week 24 (p = 
0.038), Week 36 (p = 0.044), Week 48 (p = 0.023),  Week 60 (p = 0.014), and Week 72 (p < 0.001, rank 
ANCOVA). There was no discernable treatment effect of pi[INVESTIGATOR_369253]1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 21 of 80 
 endpoint of PFS (HR 0.84; 95% CI 0.58–1.22; p = 0.35 5) or in other secondary efficacy endpoints. There 
was no protective effect on overall survival (HR 0.95;  95% CI 0.48–1.87; p = 0. 872). A total of 16 (9.4%) 
and 17 (9.8%) patients in the pi[INVESTIGATOR_7735] 2403 mg/d  and placebo groups, respectively, died. However, 
in the analyses of on-treatment mortality, the inci dence of both all-cause de aths and of RA-ILD-related 
deaths was lower in the pi[INVESTIGATOR_7735] 2403 mg/d group th an in the placebo group (9 vs. 15 deaths and 7 
vs. 14 deaths, respectively). 
[IP_ADDRESS]  Efficacy Results Across Early Trials  
PI[INVESTIGATOR_16335]-[ADDRESS_462329]. There was a marked reduction in the 
mean decline from Baseline in %FVC in patients  receiving pi[INVESTIGATOR_7735] 2403 mg/d compared with 
placebo at Week 72 (p = 0.005, rank  ANCOVA), with the positive tr eatment effect of pi[INVESTIGATOR_369254] 12 (p = 0.003) and sustained throug hout every subsequent study time point:  Week 
24 (p < 0.001), Week 36 (p < 0.001), Week 48 (p  < 0.001), and Week 60 (p < 0.001). A repeated-
measures analysis of the overall pi[INVESTIGATOR_369255] %FVC across all study time 
points also showed a strong benefit compared with  placebo (p < 0.001). The proportion of patients 
with a decrement of ≥10% from Baseline in %FVC at Week 72,  a threshold repeatedly found to predict 
mortality (Collard et al. 2003, Flaherty et al. 2003, King  et al. 2005) was 30% low er in patients receiving 
pi[INVESTIGATOR_7735] 2403 mg/d than in patients  receiving placebo (21.5% vs. 30.5%). 
In addition, treatment with pi[INVESTIGATOR_7735] 2403 mg/d res ulted in a 26% reduction in the risk of death or 
progression of disease relative to placebo (HR 0.74; 95% CI 0.57–0.96;p = 0.025) , as well as a reduced 
mean decline from Baseline in 6MWT distance at Week 72 (-52.8 m vs. -76.8 m; absolute difference of 
24 m; p < 0.001) and at all earlier study time point s after Week 12. Despi[INVESTIGATOR_369256], the risk of death in the pi[INVESTIGATOR_7735] 2403 mg/d group relative to placebo 
was reduced by 23% (HR 0.77; 95% CI 0.47–1.28; p = 0. 315), with 7.8% and 9.8% of patients in the two 
groups dying. In the  analyses of on-treatment mo rtality, the incidence of all-cause death was 35% 
lower in the pi[INVESTIGATOR_7735] 2403 mg/d group than in the placebo group (19 vs. 29 deaths), and the 
incidence of IPF-related deaths was 52% lower in the pi[INVESTIGATOR_7735] 2403 mg /d group than in the 
placebo group (12 vs. 25 deaths).  
PI[INVESTIGATOR_16335]-004, PI[INVESTIGATOR_16335]-006, SP3, and SP2 
Standardized estimates of the magnitude of the t reatment effect on FVC/VC were derived from PI[INVESTIGATOR_16335]-
004, PI[INVESTIGATOR_16335]-006, SP3, and SP2 to facilitate a direct comp arison of study results (Figure 1-1). PI[INVESTIGATOR_16335]-004 and 
PI[INVESTIGATOR_16335]-006 analyzed change from Baseline in %FVC  at time points that included Weeks 24, 36, 48, and 
72, whereas SP3 and SP2 assessed the change from Ba seline in VC at time points that included Weeks 
28 and 36. SP3 also included an assessment at Week 52 . The results show a high level of consistency in 
these results across time points (with the exceptio n of Week 72) and across these studies. In addition, 
all of the meta-analysis estimates favor pi[INVESTIGATOR_369257]. At the Week 48/[ADDRESS_462330] ratios for PFS was found for the 3 studies that included this 
endpoint (i.e., PI[INVESTIGATOR_16335]-004, PI[INVESTIGATOR_16335]-006, and SP3): a rece nt independent meta- analysis by [CONTACT_369360] (Spagnolo 2010) of these three Phase 3 trials (N = 1046) demonstrated significant 
improvement in PFS, with an overall 30% reduction in the risk of death or disease progression (HR 
0.70; 95% CI 0.56, 0.88; p = 0.002). 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462331] on VC/FVC Across Time Points 
Line represents standardized treatment effect of pi[INVESTIGATOR_369258]. placebo and 95% confidence interv al. The dose of pi[INVESTIGATOR_7735] w as 2403 mg/d in PI[INVESTIGATOR_16335]-004 and 
PI[INVESTIGATOR_16335]-006 and was 1800 mg/d in SP3 and SP2. 
 

TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 23 of 80 [IP_ADDRESS]  InterMune Pooled Phase 3 Safety Data  
Safety results from the pooled PI[INVESTIGATOR_16335]-004 and PI[INVESTIGATOR_16335]- 006 pi[INVESTIGATOR_7735] 2403 mg/d study population were 
similar to those in previous studies. Common t reatment-emergent adverse events (AE) that 
occurred more frequently in the pi[INVESTIGATOR_369259] (nausea, diarrhea, dyspepsia, vomiting, and stomach discomfort), skin disorders (rash and 
photosensitivity reaction), anorexia, decreased a ppetite, fatigue, and dizziness. Although more 
pi[INVESTIGATOR_7735] 2403 mg/d than placebo patients had at least [ADDRESS_462332] 1 day, dose 
reductions implemented in accordance with the pr otocol-specified guidelines tended to be short-
lived and were typi[INVESTIGATOR_369260]. The rate of 
treatment discontinuation due to an AE in the pi[INVESTIGATOR_7735] 2403 mg/d group was only 6% higher 
than in the placebo group. Mild or moderate seru m transaminase elevations (serum ALT or AST >3 × 
upper limit of normal [ULN]) occurred more frequent ly in patients treated with pi[INVESTIGATOR_7735] 2403 
mg/d than placebo, but they were most often effe ctively managed with dose modification and not 
associated with untoward clinical consequences. More extreme elevations in serum ALT or AST (>10 
× ULN) were rare in both tre atment groups, and no instances of liver function abnormality meeting 
the criteria for Hy’s law occurred. 
Intermune ASCEND Trial 
In the ASCEND Trial, a multinational, Phase 3, double blind, placebo-controlled study, 555 patients 
with IPF were randomized to receive pi[INVESTIGATOR_7735]  2403 mg/d (n=278) or placebo (n=277).  Study 
treatment lasted from randomization until approximately [ADDRESS_462333] pati ents (94.1%) completed the study. 
In the primary efficacy analysis, treatment with pi[INVESTIGATOR_7735] 2403 mg/d resulted in a statistically 
significant reduction in the mean decline from Ba seline in percent predicted forced vital capacity 
(%FVC) at Week 52 compared with placebo (235ml  vs. 428ml; absolute difference 193ml; relative 
difference 45.1%; p <0.001, rank ANCOVA).  At week 52, the proportion of patients who had a 
decline in FVC% by 10 percentage points or had died was reduced by 47.9% in the pi[INVESTIGATOR_369261] 
(16.5% vs. 31.8%). 
In the secondary efficacy analysis, pi[INVESTIGATOR_369262] a significant betw een group difference in 
the 6-minute walk distance (25.9% in the pi[INVESTIGATOR_369263] 35.7% in the placebo group had a 
decrease in 6-minute walk distance of 50m or mo re at week 52, P=0.04) an d the combined endpoint 
of reduction in risk of death or disease progressi on (reduced by 43% in the pi[INVESTIGATOR_369261], HR 
0.57, 95% CI 0.43 to 0.77, P<0.001).  There were no differences in dyspnea as measures by [CONTACT_369361] 52 or all cause mortality.  In  a pooled analysis of all-cause mortality (555 
patients from ASCEND and 692 from CAPACITY), ther e was a reduction in the risk of death at 1 year 
by 48% (HR 0.52, 95% CI 0.31 to 0.87, P=0.01).
 
2.[ADDRESS_462334] that pi[INVESTIGATOR_369264] a 
variety of domains, including changes in lung volume (%FVC/VC) and 6MWD over time, exercise 
tolerance (change in 6MWT distance), progression-free survival time, and all-cause mortality. Thus, 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 24 of 80 pi[INVESTIGATOR_369265]-ILD, which shares  many histopathological and clinic-epi[INVESTIGATOR_369266] (including poor survival).  
Given the loss of lung volumes over time in patients with RA-ILD, this protocol is designed to evaluate 
whether pi[INVESTIGATOR_7735] 2403 mg/d reduces decline in FVC or mortality over 52 weeks, compared with 
placebo, in patients with RA-ILD. 
This is a multi-center, randomized, double blind, placebo-controlled trial to assess the safety and 
tolerability of pi[INVESTIGATOR_7735] 2403 mg/day for the trea tment of RA-associated int erstitial lung disease. 
The protocol eligibility criteria include a probable/defi nite diagnosis of RA and associated lung disease.  
These criteria must be met in patients with % predicted FVC ≥40% and % predicted DL CO ≥25% PFT 
criteria which overlap closely with eligibility criteri a in prior studies demonstrating the efficacy of 
pi[INVESTIGATOR_369267]. FVC and DL CO criteria have been minimally liberalized to optimize 
enrollment in the more limited population of patients with autoimmune ILD.  
The primary composite endpoint of progression-free surv ival represents a clinically meaningful outcome 
measure that has been demonstrated to be reliable, valid, and predictive of changes in other disease 
states (King, Bradford et al. 2014).   Exploratory e ndpoints include a number of, clinical, serologic and 
biomarker endpoints with the potential to serve as markers of response to therapy. 
Multiple previous authors have reported that a decrement in % FVC over 6 months, particularly if ≥ 10% 
in magnitude, is both clinically significant and highly predictive of mortality (Collard et al. 2003; Flaherty 
et al. 2003; Zappala et al. 2010). We have chosen to assess th e change in % FVC over the more 
prolonged duration of 12 months (52 weeks), which is twice the 6-month duration used in many of the 
studies assessing the performance characteristics of FVC. Decrements in % FVC at [ADDRESS_462335] also 
been robustly associated with mortality (Collard et  al. 2003; {Latsi, 2003 # 4006} King et al. 2005). 
Investigators propose to to test the validity and responsiveness to ch ange of patient reported outcomes 
in the TRAIL-[ADDRESS_462336] differences; facilita te drug development; and improve assessment of 
efficacy of therapeutic agents.  
Pi[INVESTIGATOR_7735] 2403 mg/d was the dose evaluated in st udies of pi[INVESTIGATOR_369268], which demonstrated 
favorable efficacy and safety res ults compared with placebo. 
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 25 of 80 2.3  POTENTIAL RISKS AND BENEFITS  
2.3.1  Known Potential Risks  
The safety of pi[INVESTIGATOR_369269] 16 studies involving 1900 subjects and patients; 
[ADDRESS_462337] received pi[INVESTIGATOR_16332] a dose of  2403 mg/d or greater. Analyses of these data 
suggest that the side effects of pi[INVESTIGATOR_369270], typi[INVESTIGATOR_369271], and related to 
tolerability rather than morbidity.  Drug-induced liver injury (DILI) in the form of transient and 
clinically silent elevations in transaminases, ha s been commonly reported and in rare cases, these 
elevations were associated with concomitant bilirubi n increases. Non-serious and serious cases of 
DILI, including severe liver injury with fatal outco me, have been reported In the post marketing 
period.  Escalation of dose over the first [ADDRESS_462338] sun 
exposure, prompt symptomatic management of into lerance, and monitoring of liver function tests 
during dosing are recommended to maximize tolerability. 
2.3.2  Known Potential Benefits  
The collective data from InterMune-sponsored PI[INVESTIGATOR_16335]-004  and PI[INVESTIGATOR_16335]-006, as well as Shionogi sponsored 
SP3 and SP2 and the ASCEND Trial, provide eviden ce that pi[INVESTIGATOR_369272] a clinically 
meaningful benefit to patients with IPF as meas ured by [CONTACT_369362], exercise tolerance, and 
progression-free survival. 
3 STUDY OBJECTIVES AND PURPOSE 
The objectives of this study of pi[INVESTIGATOR_369273]-ILD are as follows: 
1. To assess the efficacy and safety of pi[INVESTIGATOR_7735]  2403 mg/day as compared to placebo in patients 
with RA-associated interstitial lung disease.   
 
2. To explore the role of peripheral blood biomarkers in predicting disease progression and survival 
in patients with RA-associated interstitial lung disease. 
 
3. To explore a spectrum of validated questionnaires  to assess disease specific PROs including 
overall health, and perspectives on symptoms, performance and quality of life. 
  
4 STUDY DESIGN AND ENDPOINTS 
4.1  DESCRIPTION OF THE STUDY DESIGN 
This is a phase 2, randomized, double blind, placebo controlled trial of pi[INVESTIGATOR_369274].  Approx imately 270 subjects will be randomized to receive 
pi[INVESTIGATOR_7735] 2403 mg per day or placebo in a 1:1 ratio.   The primary aim of this study is to assess the 
efficacy and safety of pi[INVESTIGATOR_7735] 2403 mg/day versus placebo in patients with RA-associated interstitial lung disease.  The primary efficacy outcome is defi ned by a composite endpoint of decline from baseline 
in percent predicted FVC of 10% or greater or death  during the 52-week treatment period.  Patients will 
receive blinded study treatment from the ti me of randomization until the Week 52 Visit. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462339] meet 201 0 ACR/EULAR criteria for RA (Aletaha, Neogi et al. 
2010) as well as RA-associated ILD, as determined by [CONTACT_369363], when available, lung biopsy. Patients 
will be required to have a percent predicted FVC ≥40% and percent predicted DL CO ≥25% at screening.  
Any patient identified for the study must discontinue all prohibited  therapi[INVESTIGATOR_129528] [ADDRESS_462340] dose of study drug to assess vital  status and adverse events.   
4.2  STUDY ENDPOINTS 
4.2.1  Primary Endpoint  
The primary outcome variable of this study will be the incidence of th e composite endpoint of 
decline from baseline in percent predicted FVC of 10% or greater or death during the study 
treatment period. 
 
4.2.[ADDRESS_462341] udy will be assessed from baseline to the 52-week 
treatment period and will include: 
1. Incidence of the composite endpoint of decline fr om baseline in percent predicted FVC of 10% or 
greater during the study  period.  
2. Frequency of progressive disease as defined by [CONTACT_141374]:  
Relative decline from baseline in percent predicted FVC of ≥10%, or relative decline from baseline 
in percent predicted FVC ≥ 5% and < 10%, and ≥15% relative decline in DL CO predicted (Khanna, 
Mittoo et al. 2015)  
3. Change from baseline to end of st udy in absolute value of FVC   
4. Change from baseline to end of study of percent predicted FVC 
5. Slope  of  percent predicted FVC over study period 
6. Slope of absolute FVC over study period 
7. Time to decline of 10% or greater in percen t predicted FVC or death over study period 
8. Proportion of participants with all-cause mortality 
9. Proportion of participants with all-cause hospi[INVESTIGATOR_059] 
10. Proportion of participants with hospi[INVESTIGATOR_369227] 
11. Number of respi[INVESTIGATOR_369275]1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 27 of 80 12. Proportion of participants with and number of treatment-emergent AEs 
13. Proportion of participants with and number of t reatment-emergent serious adverse events (SAEs) 
14. Proportion of participants with and number of treatment-emergent/treatment-related AEs 
15. Proportion of participants with and number of  treatment-emergent/treatment-related SAEs 
16. Proportion of participants with and number of AEs leading to early discontinuation of study 
treatment 
17. Proportion of participants with and number of treatment-emergent death or transplant 
18. Proportion of participants with and number of  treatment-emergent RA-ILD-related mortality 
19. Change from Baseline to end of study in dyspnea,  as measured by [CONTACT_369364] 12 questionnaire 
4.2.3  Exploratory Endpoints  
Exploratory endpoints will include the following: 
1. Change from Baseline to end of study  for Disease Activity Score (DAS)  
2. Change from Baseline to end of study for RAPID3 score (RA disease activity score) 
3. Change from Baseline to end of study in  Erythrocyte Sedimentation Rate (ESR)  
4. Change from Baseline to end of st udy in C-Reactive Protein (CRP) 
5. Candidate biomarker expression in the peripheral blood of patients with RA-ILD over the study 
period of treatment and the study follow-up period 
6. Changes from Baseline to end of study in HRCT pa rameters evaluated by [CONTACT_369365] 
7. Changes from Baseline to Week 13, 26, [ADDRESS_462342]. George’s Respi[INVESTIGATOR_6015] 
(SGRQ) 
8. Changes from Baseline to Week 13, 26, 39 and 52 in Dyspnea 12 questionnaire 
9. Changes from Baseline to Week 13, 26, 39 and 52 in Leicester Cough Questionnaire (LCQ) 
10. Changes from Baseline to Week 13, 26, [ADDRESS_462343] fulfill all of th e following criteria to be eligib le for enrollment in the study:  
 
1. Age 18 through 85 years, inclusive, at Screening 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 28 of 80 2. Probable or definite diagnosis of RA accordin g to revised 2010 ACR/EULAR criteria, without 
evidence or suspi[INVESTIGATOR_369276].  
3. Diagnosis of ILD  
a. supported by [CONTACT_369351], and wh en available, surgical lung biopsy (SLB), 
prior to Screening, and 
b. presence of fibrotic abnormality affecting more than 10% of the lung parenchyma, with 
or without traction bronchiectasis or ho neycombing, on Screening and confirmed by 
[CONTACT_369366] 
4. No features supporting an alternative diagnosis on transbronchial biopsy, or SLB, if performed 
prior to Screening 
5. Attainment of the following centralized spir ometry criteria (based on local spi[INVESTIGATOR_369277]): 
a. percent predicted FVC ≥ 40% at Screening 
b. change in pre-bronchodilator FVC (measured in liters) between Visit 1 (Screening) and 
Visit 2 (Randomization) must be a <10% relative difference, calculated as: 100% * [absolute value (Visit 1 FVC – Visit 2 FVC) / Visit 1 FVC] 
c. percent predicted DL CO or TLCO ≥25 % at Screening 
d. Screening (Visit 1) pre-bronchodilator(BD) and Post-BD spi[INVESTIGATOR_369278] a central reviewer 
e. Baseline (Visit 2) Pre-BD spi[INVESTIGATOR_369279] 
 
6. Able to understand and sign a written informed consent form.  
7. For women of childbearing potential:  agreement to remain abstinent (refrain from heterosexual 
intercourse) or use two adequate methods of cont raception, including at least one method with 
a failure rate of <1% per year, during the [ADDRESS_462344] dose of study drug.  
a. A woman is considered to be of childbearing potential if she is postmenarcheal, has not 
reached a postmenopausal state ( ≥ 12 continuous months of amenorrhea with no 
identified cause other than menopause), and has not undergone surgical sterilization 
(removal of ovaries and/or uterus). 
b. Examples of contraceptive methods with a fa ilure rate of <1% per year include bilateral 
tubal ligation, male sterilization, established  and proper use of hormonal contraceptives 
that inhibit ovulation, hormone-releasing intr auterine devices, and copper intrauterine 
devices. 
c. The reliability of sexual abstinence should be evaluated in relation to the duration of the 
clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. 
8. For men who are not surgically sterile: ag reement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptiv e measures, and agreement to refrain from 
donating sperm, as defined below: 
a. With female partners of childbearing pote ntial, men must remain abstinent or use a 
condom plus an additional contraceptive method th at together result in a failure rate of  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 29 of 80 < 1% per year during the treatment period and for at least [ADDRESS_462345] refrain from donating sperm during this same period. 
 
5.2  PARTICIPANT EXCLUSION CRITERIA 
1. Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study, 
in the opi[INVESTIGATOR_871] 
2. Cigarette smoking or vapi[INVESTIGATOR_233488] 3 months of Screening or unwilling to avoid tobacco products 
throughout the study 
3. History of clinically significant environmental exposure known to cause pulmonary fibrosis (PF), 
including but not limited to drugs (such as am iodarone), asbestos, beryllium, radiation, and 
domestic birds  
4. Concurrent presence of the following conditions: 
a. Other interstitial lung disease, related to but not limited to radiation, drug toxicity, 
sarcoidosis, hypersensitivity pneumonitis, or bronchiolitis obliterans organizing pneumonia 
b.  Medical history including Human Immunodeficiency Virus (HIV) 
     c.     Medical history of viral hepatitis (positive Hep A antibody in the absence of elevated liver  
  enzymes is not an exclusion) 
5. Concurrent presence of other pleuropulmonary mani festations of RA, including but not limited to 
rheumatoid nodular disease of the lung, pleuritis/ pleural thickening, and obliterative bronchiolitis 
6. Post-bronchodilator FEV1/FVC <0.65 at Screening 
7. Presence of pleural effusion occupying more th an 20% of the hemithorax on Screening HRCT 
8. Clinical diagnosis of a second connective tissue disease or overlap syndrome (including but not 
limited to scleroderma, sjogren’s,  polymyositi s/dermatomyositis, systemic lupus erythematosus 
but excluding Raynaud’s phenomena) 
9. Coexistent clinically significant COPD/emphysema or asthma in the opi[INVESTIGATOR_369280] 
10. Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis, 
urinary tract infection, or cellulitis .  The infection should be resolved per PI [INVESTIGATOR_369236].  Any use of antibiotics must be co mpleted 2weeks prior to the screening visit. Note 
that prophylactic antibiotics are no t contraindicated or exclusionary 
11. Any history of malignancy diagnosed within 5 years of screening, other than basal cell carcinoma of 
the skin, squamous cell carcinoma of the skin, or  low grade cervical carcinoma, and/or low grade 
prostate cancer.  Criteria for low grade prostate cancer: 
x Patients with suspi[INVESTIGATOR_369281]/or DRE should have been 
evaluated by [CONTACT_369353] 
x Patients with NCCN very low risk prostate canc er (· T1c and Grade Group 1 (Gleason 6) and 
PSA <10 ng/mL and Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in 
each fragment/coreg and · PSA density <0.15 ng /mL/g) can be monitored  without intervention 
and enrolled in study. 
x Patients with NCCN low risk prostate cancer can be  monitored on a case by [CONTACT_413] (T1-T2a 
and Grade Group 1 (Gleason 6) and · PSA <10 ng/mL) and enrolled in study. 
x All other patients should be excluded. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 30 of 80  
12. History of LFT abnormalities as outlined below, or imaging, laboratory or other clinical information 
suggesting liver dysfunction, advanced liver disease or cirrhosis.  Evidence of hepatic impairment 
that in the opi[INVESTIGATOR_369282] e with drug metabolism or increase the risk of 
the known hepatotoxicity of study drug.  
 
Any of the following liver function abnormalities: 
a. Total bilirubin above the upper limit of normal (ULN), excluding patients with Gilbert’s 
syndrome; 
b. Aspartate or alanine aminotransferase (AST/SGOT or AST/SGPT) > [ADDRESS_462346]; 
c. Alkaline phosphatase > 2.[ADDRESS_462347] criteria above specified limits: 
a. Estimated glomerular filtration rate <30
 mL/min/1.73m2 
b. ECG with a QTc interval >500 msec at Screening 
19. Prior use of pi[INVESTIGATOR_369283] 
20. Use of any of the following therapi[INVESTIGATOR_6523] 28 days before Screening  and during participation in 
the study:  
a. Investigational therapy, defined as any drug  that has not been ap proved for marketing 
for any indication in the country of the participating site 
b. Potent inhibitors of CYP1A2 (e.g. fluvoxamine, enoxacin) 
c. Potent inducers of CYP1A2. 
d. Sildenafil (daily use). Note: intermittent  use for erectile dysfunction is allowed 
21. Introduction and/or modification of dose of co rticosteroids or any cytotoxic, immunosuppressive, 
or cytokine modulating or receptor antagonist agent for the management of pulmonary  manifestations 
of RA, within 3 months of screening, is an exclusion criterion for enrollm ent, with the exception of dose 
modification of systemic corticosteroids that are ma intained at or below 20 mg prednisone daily or the 
equivalent.   
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 31 of 80 However, introduction and/or modification of  dose of corticosteroids or any cytotoxic, 
immunosuppressive, or cytokine modulating or receptor antagonist agent for the management 
of extrapulmonary  manifestations of RA is not  an exclusion criterion for enrollment.  
22.  Any use of an approved anti-fibroti c medication within 28 days of screening. 
 
5.3  PARTICIPANT WITHDRAWAL OR TERMINATION 
5.3.1   Reasons for Withdrawal or Termination  
Study treatment will be discontinued for any of the following reasons: 
x Unacceptable toxicity (this may include seri ous adverse events [SAE s] related to study 
treatment) 
x Participant request or withdrawal of consent 
x Pregnancy 
x Investigator discretion 
x Termination of study by [CONTACT_8229] 
x Lung transplantation 
 
5.3.2  Handling of Participant Withdrawals or Termination  
It is critical to the integrity of this study that participants adhere to the visit schedule outlined in the 
protocol. As such, every reasonable effort should be made to convey the importance of remaining 
on study to the participants. Any participant discon tinuing study drug (Section 5.3.3) or terminating 
participation in the study (Section 5.3.4) must be  reported immediately by [CONTACT_369367] e case in an effort to ensure participant safety 
and appropriate documentation of events.  
5.3.3  Early Discontinuation of Study Drug  
Participants who discontinue study treatment before Week 52 will complete an Unscheduled Visit 
related to discontinuation of study drug and potential sa fety issues, as necessary. If such a visit would 
occur within +/- one week of a regularly scheduled vi sit at week 4-,8-,13-,26-, or 39- then the regularly 
scheduled study visit can replace an unscheduled visit,  otherwise the subject should be brought in for an 
unscheduled visit.   Whenever possible, they will cont inue to complete all scheduled study assessments 
and procedures through Week 52. Participants who permanently discontinue study drug before Week 
[ADDRESS_462348] return unused study drug. 
 
 
5.3.4  Early Termination Visit  
Participants who withdraw consen t in writing will cease all study procedures including vital status 
assessments.  These participants will complete an  Early Termination Visit (Section 7.2.2) and Visit 
12/End of Study Phone Call [ADDRESS_462349] clinically appropriate testing in preparation for lung transplantation while on 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 32 of 80 the study. Participants who receive a lung transplant during the study will discontinue study 
treatment and withdraw from study procedures.  Th ese participants will also complete an Early 
Termination Visit (Section 7.2.2) and Visit 12/End of  Study Phone Call [ADDRESS_462350] udy treatment whenever possible and appropriate. If 
the participant has interrupted study treatment for ≥28 days, a Pre-Restart Visit is required (Section 
7.2.2). The Pre-Restart Visit will be conduc ted on the day study treatment is resumed. 
Participants who restart study treatment will res ume the visit schedule based on their date of 
randomization. If a regularly scheduled visit (Weeks 13, 26, 39, etc.) coincides with the Pre-Restart 
Visit, then all of the elements of the regularly sc heduled visit should be p erformed in lieu of the Pre-
Restart Visit.  
5.3.6  Unscheduled Visits  
Any follow-up that is performed to monitor pa rticipant safety should be collected as an 
Unscheduled Visit (Section 7.2.2). The invest igator is responsible for review of AEs/SAEs, 
concomitant medications, oxygen use , physical examination, resting oxygen saturation, vital signs, 
and weight.  The remaining elements of the visit are up to the discretion of the investigator. Any 
additional clinical laboratory assessments should be obtained through the central laboratory. 
 
5.3.[ADDRESS_462351] to Follow-Up  
If a participant has missed a visit and is not respondi ng to telephone calls from the site (all attempts 
to contact [CONTACT_369368]), th e site will need to take  more aggressive action 
in locating the participant. The site should make at  least two attempts to contact [CONTACT_369369]’s emergency contact. If these 
attempts are not successful, a registered letter shou ld be sent to the last  known address of the 
participant. If after all of these methods are empl oyed and no contact [CONTACT_369370], 
the participant will be considered lost to follow-up. In this circumstance, the site should check the 
national death registries, where approved by [CONTACT_369371], to obtain vital 
status information for the database.   
 
5.4  PREMATURE TERMINATION OR SUSPENSION OF STUDY 
Both the Sponsor or designee and the Investigator reserve the right to terminate the study at the 
Investigator’s site, according to the terms of th e study contract. The Investigator/Sponsor or 
designee should notify the IEC/IRB and relevant national competent authorities in writing of the 
trial’s completion or early termination and send  a copy of the notification to the Sponsor or 
designee.  
The Sponsor or designee reserves the right to terminate the study overall. 
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 33 of 80 5.5  APPROVAL OF NINTEDANIB (OFEV) IN THE UNITED STATES 
 
On March 9, 2020 the U.S. Food and Drug Administr ation approved OFEV (ninteda nib) oral capsules for 
the treatment of chronic fibrosing (scarring) interstiti al lung disease (ILD), su ch as RA-ILD.   All US 
participants currently enrolled in the study were cont acted to inform them of this new information and 
affirm their desire to continue participating in the study or not.   Neither OFEV nor Pi[INVESTIGATOR_369284]-ILD in Australia, Canada, or the [LOCATION_008]. 
 
6 STUDY AGENT 
6.1  STUDY AGENT(S) AND CONTROL DESCRIPTION 
6.1.1  Source and Acquisition of Study Drugs  
Genentech will supply all study medications (pi[INVESTIGATOR_369285]). There will be [ADDRESS_462352], white gelatin capsules that are visually indistinguishable. 
 
6.1.2  Study Agent Formulation, Appear ance, Packaging and Labeling  
The contents of the pi[INVESTIGATOR_7735] 267-mg capsules are as follows: 
x Pi[INVESTIGATOR_7735] 82.15% 
x Croscarmellose sodium 8.15% 
x Microcrystalline cellulose 7.39% 
x Povidone, USP, EP 1.85% 
x Magnesium stearate 0.46% 
The contents of the placebo capsules are as follows: 
x Microcrystalline cellulose 79.99% 
x Pre-gel starch 19.5% 
x Magnesium stearate 0.5% 
x Bitrex 0.01% 
 
6.1.[ADDRESS_462353] Storage & Stability  
Study medication will be shipped to the investig ational sites at ambient temperature and should be 
stored between 15 and 30° C. DO NOT FREEZE OR REFRIGERATE. Do not use beyond the expi[INVESTIGATOR_69089]. 
 
6.1.4  Dispensing of Study Treatment  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462354] return all used and unused study treatment bottles. 
 
6.1.5  Pre-specified Dose Adjustment & Modifications  
It is the responsibility of the investigator to monitor pa rticipants as frequently as clinically indicated 
for toxicities and consistent with the instructions of the package inserts for any medication used to 
treat study participants. Refer to Section 2.1 for safety data from Genentech’s Phase 3 clinical 
studies of pi[INVESTIGATOR_7735]. 
If a participant experiences significant side effe cts, treatment of symptoms and/or temporary dose 
reductions, interruptions, or discontinuation of st udy treatment should be considered. Investigators 
have experience of using Pi[INVESTIGATOR_369286], however, a suggested dosing flowchart is attached at Appendix B.  Any such dosing modificati ons should be recorded in the participant diary. 
The medical monitor or designee will be availabl e to discuss the management of AEs and dose 
modification, as needed. 
In the event of elevated liver aminotransferase te sts, the recommendations in Table 1 should be 
followed. The medical monitor or designee may be contact[CONTACT_35976], as needed.  
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462355] Recommendation 
>3 to ≤5  × ULN 
Not accompanied  by 
[CONTACT_260499] 
(Total bilirubin >2 × ULN)  Exclude other causes (e.g. confounding medications).  
Monitor the patient closely, including repeat liver chemistry tests. If 
clinically appropriate, reduce or interrupt the dose (e.g., until liver 
chemistry test results are within normal limits). Once liver function 
tests are again within normal limits, Esbriet may be re -titrated to the 
recommended daily dose if tolerated.  
Liver function tests should be repeated at 1 month intervals until 
< [ADDRESS_462356] 
>3 to ≤5 × ULN 
Accompanied  by  
[CONTACT_238015] 
(Total bilirubin >2 × ULN)  or 
clinical signs or symptoms of 
liver injury*  
*Refer to section 6.1.19 for 
clinical signs of symptoms  Study treatment should be perm anently discontinued.  Liver 
function tests should be monitored monthly until symptoms resolve and bilirubin < [ADDRESS_462357] 
>5 × ULN Study treatment should be  permanently discontinued. Liver 
function tests should be monitored monthly until < [ADDRESS_462358] 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal 
       In the event of a QTc >500 ms ec, refer to Section 7.1.2 for instructions. 
With the exceptions noted above, study treatment may be restarted at the discretion of the 
investigator. For treatment interruptions of ≥[ADDRESS_462359] dose 
tolerable for the remainder of the study. Dosing  changes and interruptions will be recorded.  
In participants requiring hospi[INVESTIGATOR_369287], the 
investigator should consider continuing study t reatment, if appropriate. If the participant is 
hospi[INVESTIGATOR_369288], the treating physician should be encouraged 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 36 of 80 to discuss the participant’s management with th e investigator at the earliest possible time. All 
records pertaining to the hospi[INVESTIGATOR_369289]. 
All toxicities will be followed acco rding to procedures in Section 8.The ultimate decision regarding 
study treatment interruption, restart, and dose modi fication is the responsibility of the investigator. 
For example, it is the investigator's responsibility to determine whether study treatment should be 
restarted in the setting of changing toxicity grad es. Investigators are encouraged to contact [CONTACT_369372]-modification issues. 
 
6.1.6  Duration of Therapy  
Study treatment is defined as either pi[INVESTIGATOR_7735] 2403 mg/d or placebo equivalent administered in 
divided doses three times per day (TID).  Each do se should be taken with food, at the same time 
each day, preferably after each meal. 
Dose Escalation Period:  Study tre atment should be titrated over 14 days, as tolerated, to the full 
dose of 9 capsules per day (three  capsules TID), as follows: 
• Days 1–7:  one capsule TID • Days 8–14:  two capsules TID 
• Days 15-21:  three capsules TI D (maximum of 9 capsules daily) 
Stable Dosing Period:   Participants will remain on  a stable maintenance dose for the duration of the 
study period (Day 22 to Week 52) unless the dose is  reduced to manage an AE (see Section 6.1.5). 
Doses of more than 9 capsules per day are not recommended for any participant.  
6.1.7  Missed Doses  
If participants miss a scheduled dose, that dose should be skipped. Regular dosing should resume 
with the next scheduled dose. Participants should  not take any extra doses to make up for missed 
doses. 
 
6.1.8  Interruption of Study Treatment  
Any participant with an actual or anticipated interruption of study treatment for a period of ≥28 
consecutive days will be reported by [CONTACT_369373]’s medical monitor or designee to 
discuss the circumstances of the case. Once the pa rticipant restarts study treatment, the dose may 
be re-titrated as described in Section 6.1.6. A pre- restart visit is required, as described in Section 
5.3.5. 
 
6.1.9 Precautionary Measures  
Drug-induced liver injury (DILI) has been observed with pi[INVESTIGATOR_7735]. In the postmarketing period, 
non-serious and serious cases of DILI, including se vere liver injury with fatal outcome, have been 
reported. Patients treated with pi[INVESTIGATOR_260349] a hi gher incidence of ALT and/or AST elevations of 
≥3x ULN (3.7%) compared with placebo p atients (0.8%). Increases in ALT and AST ≥3x ULN were 
reversible with dose modification or treatment discontinuation. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 37 of 80  
Measure liver function promptly in patients who report symptoms that may indicate liver injury, 
including fatigue, anorexia, right upper abdomina l discomfort, dark urine, or jaundice. Dosage 
modification or interruption may be necessar y for liver enzyme elevations. See Table 1. 
 
Pi[INVESTIGATOR_369290], mainly  in the form of transien t liver enzyme elevations 
of no clinical relevance. However, clinical manifestat ions of DILI including cases with fatal outcome – 
possibly caused by [CONTACT_369374] [INVESTIGATOR_7735] – have been reported in rare instances.  
Exposure to sunlight (including sunlamps and ta nning beds) should be avoided or minimized during 
study treatment due to the possibilit y of photosensitivity reactions or rash. Participants should be 
instructed to use sunscreens that have a sun prot ection factor (SPF) of [ADDRESS_462360] ultraviolet A (UV-A) radiation, and also to wear clothing that protects against sun 
exposure and avoid concomitant medications known to cause photosensitivity reactions, if possible. 
All doses of study treatment are to be taken with food to reduce the likelihood of gastrointestinal 
symptoms. The dose titration period of [ADDRESS_462361]; however, the Investigator is ultimately  responsible for monitoring of study treatment 
inventory. Study treatment may not be used for any purpose other than that described in the protocol. 
All study treatment must be stored in a secure place with access restricted to authorized personnel. 
Participants should return all us ed and unused bottles of study tre atment at every visit. After drug 
accountability has been assessed and drug return has be en authorized by [CONTACT_24653], sites may 
return all used and unused study treatment bottle s to the distribution center or destroyed in 
accordance with site-specific standard operating procedures. 
All bottles of study treatment will be recorded in a Drug Accountability Log. The Investigator or designee 
will account for all study treatment received at the site, dispensed to  the participants, returned by [CONTACT_32346], not used, and  destroyed. All docume ntation of study treatment shipments must be 
retained. 
 
7 STUDY PROCEDURES AND SCHEDULE 
7.1  STUDY PROCEDURES/EVALUATIONS 
Informed consent must be obtained prior to Screen ing and before any study-mandated procedures take 
place. Study procedures are defined as labo ratory tests, spi[INVESTIGATOR_038], lung volumes, DL CO (carbon 
monoxide transfer capacity), ECG, HRCT scan, directed history, physical examination, vital signs, height, 
weight, and any changes to existing treatment regi mens. During the study, procedures and observations 
will be monitored to confirm that study requirements are being followed as outlined in Appendix A.    If 
any study procedure related to PFTs and imaging is deemed not acceptable for quality issues, the 
procedure should be repeated.  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 38 of 80 7.1.1  Laboratory Assessments  
Routine Clinical Laboratory Tests 
The following research related assess ments will be performed locally at each clinical site, according 
to Appendix A, as summarized below: 
x Hematology (complete blood count with pl atelet count and automated differential) 
x Serum chemistry profile (albumin, alkaline phosphatase, ALT/SGPT, AST/SGOT, total 
bilirubin, calcium, creatinine, glomerular filt ration rate (eGRF), gamma-glutamyl transferase 
[GGT], glucose, potassium, sodium, BUN, uric acid and amylase) 
x Blood Pregnancy test for women of childbearing capacity 
x Serology assessments include Erythrocyte Se dimentation Rate (ESR), Rheumatoid Factor 
(RF), C-Reactive Protein (CRP), and Cyclic Citrullinated Peptide (CCP) 
 
It is the investigator’s responsibility to perform cl inical laboratory assessments more frequently, if 
clinically indicated. 
 Biomarkers in Blood 
Research laboratory studies will be conducted at Baylor College of Medicine.  Blood samples 
obtained for research studies will be shipped to Baylor College of Medi cine.  Biomarker samples 
include Serum, Plasma, and RNA.  These sample s will be collected according to Appendix A.  Samples 
will be labeled with a unique study code and st ored at the Biorepository at Baylor College of 
Medicine for future research.   
Certain biomarkers may be differentially expressed in RA-ILD and may change as a result of 
pi[INVESTIGATOR_16347] (e.g., possibly cytokines,  chemokines, microRNA expression, and other 
cellular and molecular markers of fibrosis). The bl ood samples that are being obtained for this study 
may help identify these biomarkers and may be used to assess their response to pi[INVESTIGATOR_369291]. 
 
Genetic Polymorphisms (Assessed at  Participating Sites) 
Genetic polymorphisms have been demonstrated to alter the development and clinical course of a 
number of different diseases. The purpose of assess ing genetic polymorphisms in this study is to 
understand their potential role in the pathogen esis of RA-ILD and in clinical outcomes. 
 The assessment of genetic polym orphisms will be conducted at all institutions that agree to offer 
this assessment.  Participant participation for this assessment is voluntary and declining 
participation will in no way influence eligibility for th is study. Participants agreeing to participate will 
opt in on the informed consent form.  Blood sa mples for genetic research include DNA PAXgene 
samples.  These samples will be co llected according to Appendix A.  Samples will be labeled with a 
unique study code and stored at the Biorepository at Baylor College of Medicine for future research.   
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462362] of care for a participant may 
be used to confirm eligibility, provided they meet  all of the image acquisition and quality criteria 
required by [CONTACT_369375] 3 months before the start of the 
Screening Period (see Appendix A). Al l HRCT digital images are to be stored on a dedicated disk or 
tape at each study center. The images will be transferred electronically to the vendor tasked with interpretation and archiving of the images. 
To assess for eligibility, HRCT scans will be evaluated for: 
a.  presence and extent (to nearest 10% ) of reticular abnormality, ground glass, 
honeycombing, mosaic attenuation, nodules, c onsolidation, emphysema, overall extent 
of fibrosis.  
  b.       Semi-quantitative estimates of extent by [CONTACT_39582]. 
c.        Presence of traction bronchiectasis , non-traction bronchiectasis (common in RA), 
subpleural sparing, centrilobular nodularity, tree in bud, crazy paving, pleural thickening and/or effusion.  
  d.       Distribution of abnormalities:       i.     Subpleural, peribronchovascular predominance or diffuse in axial plane      ii.    Upper lung, mid lung, lower lung  predominance or diffuse in craniocaudal plane 
e.       Radiologic pattern of abnormality: UI P, NSIP, indeterminate, mixed (Lynch DA, Godwin 
JD, Safrin S, Starko KM, Hormel P, Br own KK, et al. High-resolution computed 
tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005 Aug 15;172(4):488-93.) 
The HRCT scans will be reviewed by a central reader who is a radiologist wi th expertise in RA-ILD prior to 
randomization.  An adjudication committee will be availa ble to assist with difficu lt cases. Data regarding 
the HRCT interpretation will be entered electronica lly into the Data Coordin ating Center (DCC) database 
and incorporated into the clinical database.  Surgical lung biopsy  
Surgical lung biopsy (SLB) or transbronchial biopsy, if performed, may be obtained up to 4 years before 
randomization. Data regarding the pathology findings w ill be entered directly into the electronic case 
report form (eCRF).  Participant elig ibility will be communicated to th e study site by [CONTACT_473]’ 
designated vendor. 
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 40 of 80 Spi[INVESTIGATOR_369292]/ TLCO Measurements 
All equipment, procedures, and personnel qualifications for the assessment of lung function are based on 
the recommendations of the American Thoracic Society (ATS 2005) and will be performed and interpreted 
in accordance with publis hed guidelines (Crapo 1994):  
Spi[INVESTIGATOR_369293] 1 before and 10-15 minutes after administration of a 
bronchodilator [albuterol (or salbutam ol) from a metered dose inhaler] at screening.  The remainder of 
the spi[INVESTIGATOR_369294] d without bronchodilator administration. 
Lung volume measurements will be performed by [CONTACT_369376] [ADDRESS_462363] bronchodilator puff. 
DLCO/ TLCO will be measured by [CONTACT_369377].  
DLCO/ TLCO measurement should be performed before or at least [ADDRESS_462364] bronchodilator 
puff. 
All FVC data collected throughout the study will be evaluated by a central reader blinded to treatment 
assignment. Data for FVC and FEV 1, will be entered electronically into the vendor’s database and 
incorporated into the clinical database.   DL CO/ TLCO  will be entered into the clinical database by [CONTACT_779].   
 
Patient Reported Outcomes 
A spectrum of validated questionnaires will be used to assessed patient related outcomes that include 
disease specific, overall health, and their perspectiv es on symptoms, performance and quality of life. 
These questionnaires have been endorsed by [CONTACT_369378]- Interstitial Lung Disease. Domains that are advocated 
include:  1. Health Related Quality of Life (HRQOL), 2. Dyspnea, 3. Cough, 4.  Patient Global Assessment, 
and 5. Function.  
a) HRQOL instrument: St. George’s Respi[INVESTIGATOR_369295] (SGRQ): SGRQ, a respi[INVESTIGATOR_3765]-
specific HRQOL instrument that was originally develo ped for use in chronic obstructive pulmonary disease, 
has more recently been used in interstitial lung disease.  
b) Dyspnea: Dyspnea 12 questionnair e (D-12):  The D-12 is a unidime nsional questionnaire with 12 items 
that provides a global score of breathlessness sev erity that incorporates both “physical” and “affective” 
aspects. The score is calculated using simple summati on of the responses for each item (0 “mild” to 3 
“severe”); thus, the total score ranges from 0 to 36, with 36 representing maximal severity. It has been 
validated in Connective Tissue Disease-Interstitial Lung Disease. 
c) Cough: Leicester Cough Questionnaire (LCQ): Th is self-administered 19-item questionnaire for the 
quantitative assessment of symptoms of cough frequency and severity.  
d) Patient global assessment (DAS28 Section B Global Health Questionna ire): DAS28 Section B Is a single 
item visual analog scale that assesses global se verity of the patient due to their disease. 
e) Function: Health assessment questionnaire (HAQ20 ): It is a 20-item questionnaire to assess daily 
functional disability. It is validated in RA and is  universally used in clinical trials of RA. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 41 of 80 f) RAPID3: The Routine Assessment of Patient Index Data 3 (RAPID3) is a questionnaire that has been   
validated for rheumatoid arthritis to assess patien t physical function, pain, and global assessment. 
Physical Exam and Vital Signs 
A complete physical examination should be performed on the day of the visit, including all body systems 
pertinent to the participant. If clinically significan t abnormalities are observed before Day 1, they should 
be reported in the participant’s medical history. If cl inically significant abnormalities are observed after 
Day 1, the investigator should decide if they are new adverse events.  Vital signs for this study protocol 
include heart rate and blood pressure.  
Disease Activity Score (DAS28) 
The DAS28 will be scored by [CONTACT_369379] b results (ESR and CRP), as well as patient global 
assessment score.   
Physician Global Assessment 
Physician Global Assessment questionnaire asks physician s to rate the patient’s overall health in the last 
week. 
Vital Status Assessments 
Vital status must be assessed at protocol-specified time points until the Follow-Up Visit, even if the 
participant cannot physically be present for the visi t. Participants who chose to withdraw from study 
procedures early will be followed for vital status until Visit 12/End of Study Phone Call whenever 
possible.  
Vital status procedures are as follows: 
1. In the case of lung transplant, the date of th e transplant, details of the transplant, dates of 
hospi[INVESTIGATOR_059], and the current vital status will be obtained 
2. In the case of participant death, the date, details , and cause of death will  be obtained if possible 
3. If a participant is lost to follow-up, vital stat us will be ascertained through the use of Death 
Registries, where approved and available (see 5.3.7) 
Mortality Assessment Committee 
A Mortality Assessment Committee (MAC) will closely examine the details and review the relationship to 
RA-ILD for each death. Documentation regarding deaths must be requested and should include (but is not 
limited to) discharge summaries, death certificates, and autopsy reports. 
 
Adjudication of Acute Exacerbations 
An adjudication committee will be established to assess whether epi[INVESTIGATOR_369296]/acute exacerbation are congruent with  established criteria, and their relationships to 
study treatment. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 42 of 80  
Electrocardiograms (ECGs) 
ECGs should be performed before bronchodilato r administration or on a separate day. 
During the study, if the QTc interval is >[ADDRESS_462365], 
study treatment should be interrupted. If an altern ative explanation is identified (e.g., electrolyte 
abnormality or concomitant medication), re-initiat ion of study treatment may be considered by [CONTACT_369380]. ECG data will be incorporated into 
the clinical database. 
 
 
7.[ADDRESS_462366] to  change over time such as a condition that 
subsequently resolves (e.g. infection), change  in concomitant medication (e.g. dose of 
corticosteroids is stabilized or a prohibited medic ation has been completed/discontinued), change in 
smoking history (e.g. smoking history now greater than within 3 months of screening), spi[INVESTIGATOR_369297], or lab assessment criteria.  In such cases,  all Visit [ADDRESS_462367] scans 
performed within 3 months of the start date of  the screening period may be used to confirm 
eligibility. 
 
Screening (Visit 1)  
The Screening period (Visit 1) is defined as the time between the date of the first Screening 
procedure and Eligibility/Randomization (Visit 2) an d may last up to 56 days. Screening procedures 
may be conducted on differen t days within the Screening period if convenient. 
The following procedures will be performed during Screening: 1.   Written informed consent 2.   Directed medical history/review of systems,  review of AEs/SAEs, concomitant medications, 
oxygen use  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462368] for women of childbearing capacity 
5.   ECG (obtained before bronchodilator administration or on a separate day) 
6.   Measurement of Oxygen Saturation at Rest 
[ADDRESS_462369] scan to assess eligibility 
9 .  Spi[INVESTIGATOR_038] (FVC, FEV 1) before and 10-15 minutes after bronchodilator administration 
10. Lung volumes, DL CO or TL CO obtained before or 30 minutes aft er bronchodilator administration 
11. Biomarkers (See Appendix A) 
 
Eligibility and Randomization (Visit 2) 
 
All Visit [ADDRESS_462370] be performed before randomization and before administration of study 
treatment.  Randomization (Visit 2) will occur no more than [ADDRESS_462371] 2 working days before the targeted randomization day. Once a participant’s 
documentation is received and the participant is conf irmed to be eligible for randomization, the site 
will be instructed to randomize the participant at the end of Visit 2. 
The following procedures will be performed at Visit 2:  
Before Randomization: 
1. Directed medical history/review of systems,revie w of AEs/SAEs, concomitant medications, oxygen 
use 
2.  Physical examination, resting oxygen saturation, vital signs, and weight 3. Pregnancy test for women of childbearing capacity 4.  Biomarkers (See Appendix A)  5. Blood samples for genetic research (DNA PAXgene samples) - Optional 6.  Spi[INVESTIGATOR_038] (FVC, FEV 1) without bronchodilator administration 
7.  Patient Reported Outcome Qu estionnaires (See Appendix A) 
8. Disease Activity Score (DAS28): Swollen and Tender Joint Counts and p atient global assessment 
score 
9. Confirmation of participant eligibility for study participation 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 44 of 80 Randomization: 
10. Randomize participant us ing an automated system 
After Randomization: 
11. Instruct the participant on how to titrate the dose of study treatment 
12. Dispense supply  of study treatment.  On day of randomization, first dose must be taken in clinic 
and Study Medication Accountability completed. 
13. Dispense participant diary and instruct partic ipants on how to properly record information using 
the diary 
 
7.2.2  Assessments During Treatment  
 
Weeks 1 and 2 (Visit 3, 4) (± 2 days) Telephone Assessment  
A telephone interview will be conducted for Vital S tatus Assessment, review of AEs/SAEs, concomitant 
medications, and study medication dosing.  
Weeks 4 and 8 (Visit 5, 6) (± 1 week) 
 
The following procedures will be  performed at Weeks 4 and 8: 
1.   Review of AEs/SAEs, concomitant medications, oxygen use 
2.   Physical examination, resting oxygen saturation, vital signs, and weight 
3.   ECG (at Week 4 only)  4.   Clinical laboratory assessments, including hematology, serum chemistries, and blood pregnancy 
test for women of childbearing capacity 
5. Study Medication Dosing review (participant diary) 
6. Biomarkers (Week 4 only) 
 
Weeks 13, 26, 39 (Visit 7, 9, 10)  (± 2 weeks) 
 
The following will be performed at Weeks 13, 26, and 39: 
1.   Review of AEs/SAEs, concomitant medications, oxygen use 
2.   Physical examination, resting oxyg en saturation, vital signs, and weight 
3.   ECG  
4.   Spi[INVESTIGATOR_038] (FVC, FEV 1) without bronchodilator administration 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462372] 
for women of childbearing capacity 
6.   Biomarkers 
7.   Patient Reported Outcome Questionnaires (See Appendix A) 
8.   Study Medication Accountability, including dispensing of study treatment 
9.   Study Medication Dosing review (participant diary) 
10.   Dispense new diary, if required. 
 
Week 19 (Visit 8) (± 1 week) 
 
The following will be performed at Week 19: 
1. Review of AEs/SAEs, concomitant medications 
 
2. Liver function testing only (AST, ALT, bilirubin, and alkaline phosphatase) 
 
Week 52 (Visit 11) (± 4 weeks) 
 
At the Week 52 Visit, the following procedures will be performed: 
1. Review of AEs/SAEs, concomitant medications, oxygen use 
2.  Physical examination, resting oxygen saturation, vital signs, and weight 
3. Clinical laboratory assessments, including hem atology, serum chemistries, serologic tests, and 
blood pregnancy test for women of childbearing capacity 
4.  Biomarkers (See Appendix A) 
5. Blood samples for genetic research (DNA PAXgene samples) - Optional 6.  Spi[INVESTIGATOR_038] (FVC, FEV1 without bronchodilator administration) 7.  Lung volumes, DL CO or TL CO  
8.  Patient Reported Outcome Qu estionnaires (See Appendix A) 
9. Study Medication Accountability, including  collection of any unused study treatment 
10. Study Medication Dosing review (participant diary) 11. HRCT scan 
12. ECG 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 46 of 80 13. Disease Activity Score (DAS28): Swollen and Te nder Joint Counts and pati ent global assessment 
score 
 
Visit 12/End of Study Phone Call ([ADDRESS_462373] dose of study drug, ± 1 week) 
 1. Review of AEs/SAEs 
 2. Vital Status Assessment 
 
Early Termination Visit 
Participants who terminate participation in the st udy (e.g. withdraw consen t in writing, receive a 
lung transplant) will discontinue study treatmen t, cease all study procedures, and undergo the 
assessments listed below.  These participants will  also complete Visit 12/End of Study Phone Call [ADDRESS_462374] dose of study drug. 
 
1. Review of AEs/SAEs, concomitant medications, oxygen use 
2. Physical examination, resting oxygen saturation, vital signs, and weight 
3. Clinical laboratory assessments, including hema tology, serum chemistries, serologic tests, and 
blood pregnancy test for women of childbearing capacity 
4. Biomarkers (See Appendix A) 
5. Blood samples for genetic research (DNA PAXgene samples) - Optional 
6. Spi[INVESTIGATOR_038] (FVC, FEV1 without bronchodilator administration) 
7. Lung volumes, DLCO or TLCO 
8. Patient Reported Outcome Qu estionnaires (See Appendix A) 
9. Study Medication Accountability, including  collection of any unused study treatment 
10. Study Medication Dosing review (participant diary) 
11. HRCT scan 
12. ECG 13. Disease Activity Score (DAS28): Swollen and Te nder Joint Counts and p atient global assessment 
score 
 
Study Treatment Pre-Restart Visits 
If the participant has interrupted study treatment for ≥28 days, a Pre-Restart Visit is required.  
The following procedures will be p erformed at the Pre-Restart Visit: 
 1. Review of AEs/SAEs, concomitant medications, oxygen use 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462375] for women of childbearing capacity 
4. ECG 
5. Study Medication Accountability, including dispensing of study treatment, if required 
6. Study Medication Dosing review (participant diary) 
7. Instruction on how to re-titrate the dose of study treatment 8. Dispense new diary, if required 
 
Unscheduled Visits 
The following procedures are required to be perfor med at Unscheduled Visits to monitor participant 
safety: 
1. Review of AEs/SAEs, concomitant medications, oxygen use 
2. Physical examination, resting oxygen saturation, vital signs, and weight 
3.  Study Medication Accountability 4. Study Medication Dosing review (participant diary) 
 
Further evaluation as part of routine clinical ca re would be done at the discretion of the site 
Principal Investigator.  
Participants who discontinue study drug early will complete an Unscheduled Visit.  These 
participants will then continue to complete all scheduled study assessment s and procedures through 
Week 52 (Visit 11). 
 
7.3  CONCOMITANT MEDICATIONS & TREATMENTS DURING THE STUDY 
7.3.[ADDRESS_462376] be 
collected and recorded: • Prescription drugs • Over-the-counter drugs, including vitamins,  antacids, herbal and dietary supplements 
• Permitted therapi[INVESTIGATOR_014] (see section 5.1) 
• Excluded therapi[INVESTIGATOR_014] (see Section 7.4) 
Information on all concomitant medications will be collected until [ADDRESS_462377] dose of 
study treatment.   
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 48 of 80 7.3.2 Treatment for Acute ILD Exacerbations  
Acute ILD exacerbations should be identified in  accordance with published guidelines.(Raghu, 
Collard et al. 2011)  Corticosteroids may be used at the discretion of the investigator, without dose 
restriction, for a period of up to 21 days in part icipants experiencing an epi[INVESTIGATOR_369298]. The study drug should be continued during this time, if possible. If study treatment 
interruption/discontinuation is being considered, it  must be immediately reported by [CONTACT_369381]. 
 
7.4  PROHIBITED MEDICATIONS AND TREATMENTS DURING THE STUDY 
Pi[INVESTIGATOR_369299] P450 1A2 (C YP1A2). Inhibitors of this  enzyme will increase 
drug levels and inducers reduce them. Potent inhibi tors and activators should be avoided. Use of 
medications with moderate and mild activator and inhi bitor effects on study drug metabolism is left to 
the discretion of the site PI. 
The following medications are not permitted on this st udy - strong inhbitors of CYP1A2 including but not 
limited to Fluvoxamine and Enoxacin. 
The following moderate inhibitors of CYP1A2 medications should be used with caution: Amiodarone, 
Propafenone, Ciprofloxacin. Pi[INVESTIGATOR_369300] 1602 mg da ily (2 capsules, 3 times a day) 
if taken with Ciprofloxacin 750mg tw ice daily. Special care should also be  exercised if CYP1A2 inhibitors 
are being used concomitantly with potent inhibitors of one or more ot her CYP isoenzymes involved in 
the metabolism of pi[INVESTIGATOR_369301]2C9  (e.g. amiodarone, fluconazole), 2C19 (e.g. 
chloramphenicol) and 2D6 (e.g . fluoxetine, paroxetine).  
Moderate inducers of CYP1A2 may reduce the effect ive dose of pi[INVESTIGATOR_369302].  
 
 
[ADDRESS_462378] entered this study and 
for providing appropriate medical care. In additi on, the investigators are responsible for alerting 
Genentech and/or [COMPANY_002] or its designee to any ev ent that seems unusual, even if the event may be 
considered an unanticipated benefit to the participan t. A SAE should be reported to the medical monitor 
or designee within [ADDRESS_462379] report all SAEs to their govern ing IRB/IEC as required by [CONTACT_311873]. 
By [CONTACT_369382]-care options, the in vestigator remains responsible for managing AEs that 
are serious or that cause the participants to withdraw  before completing the study. Duration of follow-up 
and requirements for immediate SAE reporting (within 24 hours of the event) are described below. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 49 of 80 8.2  SAFETY DATA EXCHANGE AGREEMENT 
 
8.2.1  Background  
The relevant International Conference on Harmonizat ion (ICH) guidelines, the latest European Union 
Pharmacovigilance guidelines and applicable Europe an Union legislation, the [LOCATION_002] (US) 
Code of Federal Regulations, Title 21, and rel evant local regulations form the basis of the 
information to be exchanged under this protocol and to be reported to the regulatory authorities, as 
applicable.  
 
8.2.2  Definitions  
 
Single Case Management  
x Collection of Single Case Reports 
o The PI [INVESTIGATOR_28678] (i.e., the DCC) will  collect all protocol-defined Adverse Events 
(AEs) and pregnancy reports from the Study and obtain follow-up information on incomplete AE and pregnancy reports. 
x Tracking of Safety Information 
o The PI [INVESTIGATOR_28678] (i.e., the DCC) will track all protocol-defined AE and pregnancy 
reports originating from the Study for the Pro duct. The PI [INVESTIGATOR_369303] (SAD Rs) associated with other Investigational Medicinal 
Products (IMPs), (i.e., excluding the Pro duct), as defined in the protocol.  
Exchange of Single Case Reports 
 
Serious Adverse Events (SAEs), pregnancy reports, where the part icipant has been exposed to 
the Product, will be sent on a MedWatch or CIOM S I form to the [COMPANY_002] contact [CONTACT_369383]. 
Transmission of these reports (initial and follow- up) will be either electronically or by [CONTACT_369384]: 
 
x SADRs 
Serious AE reports that are related to the Pro duct or where the causality is assessed as 
unknown or not provided shall be transmitte d to [COMPANY_002] via the Data Coordinating Center 
(DCC) within fifteen (15) calendar days of the awareness date.  
x Other SAEs 
Serious AE reports that are unrelated to the Product shall be transm itted to [COMPANY_002] via the 
DCC within thirty (30) calendar days of the awareness date. 
 
x Pregnancy reports 
While such reports are not serious AEs or Adv erse Drug Reactions (ADRs) per se, any reports 
of pregnancy, where the fetus may have been ex posed to the Product, shall be transmitted 
to [COMPANY_002] via the DCC within thirty (30) ca lendar days of the awareness date. Pregnancies 
will be followed-up until the outcome of the pr egnancy is known, whenever possible, based 
upon due diligence taken to obtain the follow-up information. 
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 50 of 80 [Note: For all reports, an acceptable format includes MedWatch or CIOMS I form, or [COMPANY_002] 
approved reporting forms. If the Sponsor is unable to use these formats then line-listings 
can be used as detailed in the Global: Investigator Initiated Study Safety Data Exchange 
Management (WI-0100195).]  
 
Case Transmission Verification of Single Case Reports 
 
The investigators will ensure that all single case  reports have been adequately received by 
[CONTACT_26702], via a periodic line-listing documenting single  case reports sent by [CONTACT_978] [INVESTIGATOR_369304] (e.g., monthly).  Confirmation of receipt should be received wi thin the time period mutually agreed upon. 
 
Following Case Transmission Verification, single case reports which have not been received by [CONTACT_369385] (via the DCC) to [COMPANY_002] within five (5) calendar days from request by [CONTACT_26702]. 
 
8.2.[ADDRESS_462380] reports that are serious and unexpected, unless otherwise agreed 
with applicable regulatory authorities. 
8.2.4  Reporting to Regulatory Authorities,  Ethics Committees and Investigators  
The PI [INVESTIGATOR_369305] a clinical trial approval, in compliance 
with local regulations. 
The PI [INVESTIGATOR_369306] (EVCTM).The PI [INVESTIGATOR_369307], where applicable. 
The PI [INVESTIGATOR_369308], where 
relevant, in accordance with local regulations. 
The PI [INVESTIGATOR_369309]-monthly S[LOCATION_003]R reports and their submission to 
investigators, regulatory authorities and Ethics Committees, where applicable.  
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 51 of 80 Aggregate Reports 
 
x Development Safety Update Report 
The PI [INVESTIGATOR_284307]  a Development Safety Update Report (DSUR) 
for the Study and for the submission of the repo rt to the regulatory authorities and Ethics 
Committees of the concerned Memb er States, where applicable. Th e PI [INVESTIGATOR_369310].  
[COMPANY_002] will forward to the PI [INVESTIGATOR_369311]. The  PI 
[INVESTIGATOR_369312]-reference the executive summary of the [COMPANY_002] DSUR, as applicable.  
 
x Other Reports 
The PI [INVESTIGATOR_369313]-seri ous AEs originating from the Study to [COMPANY_002]. 
 Queries 
Queries related to the Study will be answered by  [CONTACT_978].  However, responses to all safety 
queries from regulatory authorities or for publicati ons will be discussed with [COMPANY_002]. [COMPANY_002] shall 
have the final say and control over safety queries relating to the Product. The PI [INVESTIGATOR_369314]. 
All reasonable effort will be made to ensure th at deadlines for responses to urgent requests for 
information or review of data are met.  
 
Safety Crisis Management 
In case of a safety crisis, e.g., where safety issu es have a potential impact  on the indication(s), 
on the conduct of the Study, may lead to labe ling changes or regulatory actions that limit or 
restrict the way in which the Product is used, or  where there is media involvement, the PI [INVESTIGATOR_369315].  
 
8.2.5  Language  
English will be used as the common language fo r all safety information exchanged between the 
Parties. 
8.2.6  Records 
The PI [INVESTIGATOR_369316] (or true copi[INVESTIGATOR_91678]) for a 
time period required by [CONTACT_369386], taking into account the minimum archiving period worldwide.  
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 52 of 80 8.3  AE AND SAE SEVERITY GRADES AN D RELATIONSHIP TO STUDY TREATMENT 
The seriousness of an AE should not be confused with  its severity. The severity of AEs is to be graded 
according to the following guidelines: 
Grade 1–Mild: Transient or mild discomfort; no limitation in activity; no medical intervention/ 
therapy required 
Grade 2–Moderate: Mild to moderate limitation in  activity; some assistance may be needed; no 
or minimal medical intervention/ therapy required 
Grade 3–Severe: Marked limitation in activity; some assistance usually required; medical 
intervention or therapy required, hospi[INVESTIGATOR_369317] 4–Life  Threatening: Extreme limitation in activity; significant assistance required; 
significant medical intervention/therapy requi red, hospi[INVESTIGATOR_369318] 5-Death 
The relationship of study treatmen t to the AE will be determined by [CONTACT_311874]: 
Not Related: Another cause of the event is most plausible; and/or clinically plausible temporal 
sequence is inconsistent with the onset of th e event and the study treatment administration; 
and/or a causal relationship is considered biologically implausible. 
Possibly Related: An event that follows a reasona ble temporal sequence from administration of 
the study treatment, or follows a known or ex pected response pattern to the suspected drug, 
but that could readily have been prod uced by a number of other factors. 
Probably Related: An event that follows a reasona ble temporal sequence from administration of 
the study treatment, and there is a biologically plausible mechanism for study treatment causing 
or contributing to the AE and the event coul d not be reasonably explained by [CONTACT_11347]’s clinical state. In  addition, the relationship may be confirmed by 
[CONTACT_369387][INVESTIGATOR_369319].  
8.3.[ADDRESS_462381] 7 (for non-
serious AEs or 28 days for SAEs) after the last day of study participation. At each study visit, the 
investigator will inquire about the occurrence of AE/SAE s since the last visit. Events will be followed 
for outcome information until resolution or stabilization. A record of all AEs, by [CONTACT_62444], will be 
recorded centrally by [CONTACT_15791]. 
8.3.[ADDRESS_462382] visit and study participants and their significant others will be asked in advance to 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462383] report all SAEs to their gov erning IRB/IEC, as required by [CONTACT_311873]. 
Deaths in patients who withdraw from study procedures early and continue with Vital Status 
Assessments will not be considered SAEs if the deat h occurs more than [ADDRESS_462384] of all SAEs, by [CONTACT_369388] t, will be  databas ed by [CONTACT_15791]. 
8.3.3  Unexpected Adverse Event Reporting  
All adverse events that meet the definition of an  unanticipated problem should be reported to the 
local governing IRB within specific timelines as described below: The Unanticipated Problem (UP) 
report will include the following information: 
x Protocol identifying information: protocol titl e and number, PI’s name, and the IRB project 
number; 
x A detailed description of the event, incident, experience, or outcome; 
x An explanation of the basis for determining that  the event, incident, experience, or outcome 
represents an UP; 
x A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP. 
[IP_ADDRESS]  Reporting to the IRB required within 10 working days:  
• Any internal or external adverse event ( unanticipated problem) which meets all of the 
following criteria:  a) Unexpected (in occurance, severity or in f requency of occurance that was not previously 
known and/or described in the approved informed consent document or other protocol related documents), 
b) and Related or possibly related to the research participation,  
c) and places subjects or others at greater ri sk of harm than was previously known or 
recognized  (i.e. a serious adverse event, a new or increased risk to subjects/others) 
[IP_ADDRESS] Reporting within 3 working days:  
• An SAE, including subject death, that meet all of the following criteria: 
a) Occurred in an interventional study (i.e., involving a drug, biologic, device procedure 
and/or behavioral interventions), 
b) Unexpected, 
c) and judged to be related or possibly related to research participation 
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462385] (DSMB) 
composed of individuals with the appropriate expertis e in RA-ILD, the study drugs and/or clinical trials 
research including experts in Rheumatology, Pulmonar y Medicine, Internal Medicine and/or Bioethics, 
and Biostatistics. The DSMB Chair will be appointed by [CONTACT_369389]. The DSMB Chair will then independen tly select the remainder of the Committee Members 
using similar expertise and affiliation criteria. 
Once the trial is initiated, the DS MB will review cumulative trial results to evaluate the treatment for 
adverse effects, including the review of all AEs,  SAEs and UP.  The board  will also monitor the 
performance of individual clinics and study performance indicators (drug monitoring and compliance, visit compliance, recruitment, etc.). The DSMB  will meet approximiately every 6 months by 
[CONTACT_369390]/or web videoconferencing for the du ration of the trial and will interact directly with 
the DCC for access to study data and interim reports.  
The DSMB will be charged to provide external oversight concerning the safety and scientific integrity of 
the study for the duration of the clin ical trial. Written reports will be produced that will advise study 
sites as to whether the study is approved to conti nue as is, specific safety and/or data management 
procedures will need to be addressed/implemented for ongoing approval, or whether the study should 
be stopped due to specific safety or ethical management concerns. 
The DCC will provide the DSMB with all of the study related information that it requires to carry out its 
directive.  
9 CLINICAL MONITORING 
Throughout the course of the study, data will be monitored for accuracy and completeness and study 
procedures will be monitored for ad herence to the protocol and Good  Clinical Practices (GCP). In 
addition to frequent contacts through e-mail and telephone, on-site monitoring visits will be 
coordinated by [CONTACT_369391] (SABER) unit at the 
University of Michigan.  SABER (the Data Coordin ating Center for this study) will be responsible for 
operational aspects and monitoring of the trial, incl uding at least annual monitoring visits and/or 
remote source data verification.   
The clinical monitor will ensure that: 
• Data collected and entered into the database a re verifiable against source documents for the 
participants.  The clinical monitor will need access to subject medical records and other study-related records needed to verify the entries on the electronic case report forms.   
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 55 of 80 • Appropriate consent is obtained for each participant prior to study procedures. 
• The rights and well-being of participants are being protected. 
• The study is conducted in accordance with the currently approved protocol (including study 
treatment being used in accordance with the protocol), with any other study agreements, with GCP and 
with applicable regulatory requirements. 
• Study medication is properly dispensed and acc ounted for.  The study monitor will also perform 
drug accountability checks and review the clinical site’s regulatory document binder to assure 
completeness of documentation in all re spects of clinical study conduct.   
• Details of clinical site monito ring are documented in a Clinical  Monitoring Plan (CMP). The CMP 
describes in detail who will conduct the monitoring, at  what frequency monitori ng will be done, at what 
level of detail monitoring will be performed, and the distribution of monitoring reports. 
10 STATISTICAL CONSIDERATIONS  
The objectives of the study are to assess the efficacy  and safety of pi[INVESTIGATOR_7735]2403 mg/d compared with 
placebo in the treatment of participants with RA-ILD.  A statistical analysis plan (SAP) will be written for 
the study that contains detailed desc riptions of the analyses to be performed.  The SAP will be finalized 
prior to unblinding of the data.  Baseline is defined as values from assessments and testing done during the Sceening period.  
 
10.1 RANDOMIZATION AND TREATMENT ASSIGNMENT 
Eligible participants will be screened and once dete rmined to be eligible, informed consent will be 
obtained. Participants will then be randomized with  equal probability to receive either Pi[INVESTIGATOR_369320] a double-blinded fashion.  Treatment assi gnments will not be re-used; each consecutive 
randomized participant will receive the next consecutive unused trea tment assignment.  The password 
protected computer text file that contains the translation of treatment labels A and B to either Pi[INVESTIGATOR_369321]. 
 
10.2 SAMPLE SIZE AND POWER CONSIDERATIONS 
10.2.1  Primary endpoint: 
Table 1A shows sample size calculations and Table 1B shows power that will be achieved for some 
feasible scenarios with the select ed sample size.  Hypothesized es timates of treatment response in 
both placebo and pi[INVESTIGATOR_369322] (King, 
et al., 2014.) If participants with RA-ILD are similar, then the proposed sample size of 254 
participants (127 per group) will provide 85% pow er to demonstrate the treatment difference in 
terms of the combined primary endpoint reached by  [CONTACT_5875] 52, defined as either death or a decline 
from baseline of >[ADDRESS_462386] fewer endpoints,  and 
showing the robustness of the power to slight deviations from the hypothesized treatment 
estimates with the selected sample size. The number of participants randomized will be 270  
because of possible loss of data due to participan ts droppi[INVESTIGATOR_369323] 52 or other reasons. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 56 of 80 PASS version 13 was used for power calculations (PAS S 13 Power Analysis and Sample Size Software, 
2014, NCSS, LLC. Kaysville, Utah, US A, ncss.com/software/pass.).    
 
Table 1: Power analysis for combin ed major endpoint reached by [CONTACT_5875]  52, defined as either death or 
a decline from baseline of >10 percentage  points in the percent predicted FVC. 
 
A. Sample Size Calculation, 5% alpha, 2-sided 
Power Sample Size Each 
Arm Total Sample 
Size Proportion 
Placebo Proportion 
Pi[INVESTIGATOR_369324] 
0.80 
0.85 
0.90 0.80 
0.85 
0.90 141 
161 
188 111 127 
148 282 
322 376 222 
254* 
296 0.30 
0.30 0.30 0.32 
0.32 
0.32 0.16 
0.16 0.16 0.16 
0.16 
0.16 0.14 
0.14 0.14 0.16 
0.16 
0.16 
*  The anticipated total number of participants is 254. 
B. Possible Scenarios with fewer endpoints, 127 on  each arm (254 total), 5% alpha, 2 sided. 
Proportion 
Placebo Proportion Pi[INVESTIGATOR_369325] 
0.24 0.08 0.16 0.94 
0.24 0.10 0.14 0.85 
0.24 0.11 0.13 0.78 
0.26 0.08 0.18 0.97 
0.26 0.10 0.16 0.92 
0.26 0.12 0.14 0.82 
0.28 0.12 0.16 0.89 
0.28 0.13 0.15 0.85 
0.28 0.14 0.14 0.79 
0.29 0.13 0.16 0.88 
0.29 0.14 0.15 0.83 
0.29 0.15 0.14 0.77 
0.30 0.14 0.16 0.87 
0.30 0.15 0.15 0.82 
0.30 0.16 0.14 0.76 
0.31 0.15 0.16 0.86 
0.31 0.16 0.15 0.81 
0.32 0.15 0.17 0.90 
0.32 0.16 0.16 0.85 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 57of 80Figure 1:
10.2.2 Secondary and exploratory endpoints:
All analyses of secondary outcomes will be explorat ory.  Observed effect sizes will be useful to 
inform the design of future confirmatory tr ials and provide supportive information about 
consistency or lack thereof of pi[INVESTIGATOR_369326]. Additional exploratory analyses will 
incorporate data from Quantitative Imaging Analys is of Parenchymal Lung Abnormalities, data from 
Biomarker Analysis, and Patient Reported Assessments as described in the assessments and study objective sections above.
10.3 ADVERSE EVENTS
Table 2A shows the probability of observing at leas t one adverse event among participants randomized 
to Pi[INVESTIGATOR_369327] a range of assumptions for the background adverse even t rate.  The proposed 
sample size of 127 participants randomized to Pi[INVESTIGATOR_369328] a 72% probability of observing an 
adverse event with a 1% background rate and a 99% probability of observ ing an adverse event that has a 
3.5% background rate.  Furthermore, with a goal of es timating an adverse event rate for this population 
with sufficient precision based on the proposed sa mple size, Table 2B shows that the two-sided 95% 

TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 58 of 80 confidence interval around the observed proportion will be sufficiently narrow for a range of adverse 
event rates. 
Table 2A:   Probability of observing at least one adverse event in the pi[INVESTIGATOR_369261] (N=127), under a 
range of background adverse event rates.  
Background Adverse Event Rate Probability of Observing at Least 
One Adverse Event 
0.010 0.72 
0.020 0.92 
0.035 0.99 
0.050 1.00 
0.100 1.00 
0.150 1.00 
0.200 1.00 
 
Table 2B:   Two-sided 95% confidence interval width for a range of observed adverse event proportions 
with 127 participants on Pi[INVESTIGATOR_369329].   
Observed Proportion Confidence Interval Width Lower Limit Upper Limit 
0.025 
0.050 
0.075 
0.100 
0.125 
0.150 
0.175 
0.200 0.064 
0.084 0.100 
0.112 
0.122 
0.131 
0.139 
0.146 0.006 
0.019 0.036 
0.054 
0.073 
0.093 
0.113 
0.134 0.069 
0.104 0.135 
0.166 
0.195 
0.224 
0.252 
0.280 
    
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 59 of 80 10.4 STATISTICAL ANALYSIS 
10.4.1  Analysis Populations  
The intention to treat (ITT) population will include all participants randomize d and will be used to 
assess primary, secondary and exploratory effi cacy outcomes.  The as-treated population will 
include all randomized participants who received at least one dose of study medication and will be 
used to assess safety outcomes.  An additional sec ondary analysis dataset will be used to assess the 
robustness of the primary efficacy endpoint:  Th e per protocol dataset is defined as the ITT 
population excluding patients who are noncompliant  with study medication and who have major 
protocol deviations.   
10.4.2   Efficacy Analyses  
Demographic data and baseline characteristics will be  summarized by [CONTACT_2939].  The primary 
analysis population will be the ITT population. The main analysis framework will be logistic 
regression to assess treatment differences in the primary outcome, defined as either death or a 
decline from baseline of >10 percentage points in  percent  predicted FVC, reached by [CONTACT_5875] 52.  
Baseline for spi[INVESTIGATOR_369330] g visit with the assumption that values are the 
same at randomization. Baseline for other variab les is defined as the randomization visit for 
variables collected at randomization, otherwise as the screening visit. The main predictor will be 
treatment arm, and covariates known to be related to the outcome and specified a priori (i.e., prior 
to database lock and unblinding), will be considered  for inclusion.  The stratification factor will be 
the site. Unadjusted and adjusted odds ratios, 95% confidence intervals and Wald test p-values will 
be reported.  Similar analyses will be conducte d with the listed secondary binary outcomes in 
Section 4.2.2.  An additional secondary analysis  of the primary endpoint will use the Per Protocol 
population.   
Statistical analyses of the secondary outcomes that  describe time-to-event will use Cox proportional 
hazards regressions using a similar approach as de scribed above, reporting adjusted hazard ratios, 
95% confidence intervals and p-values.  Time w ill be measured from randomization until the event 
or until censoring.   Kaplan-Meier plots will be generated, and proportionality of hazards will be 
assessed.   
There are a number of secondary and exploratory ou tcome variables that are continuous, that will 
be calculated for each subject as  follows:  Each change from baseline to week [ADDRESS_462387]. 
Analyses of secondary and exploratory endpoints an d secondary analyses of the primary endpoint 
will be reported as exploratory.   
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462388] summary 
statistics and group comparisons (e.g., Chi square or  Fisher’s exact test) for adverse events, as well 
as lists of participant-level data where relevant. Time-to-event analyses will also be reported for 
select safety outcomes, for example for hospi[INVESTIGATOR_3094], transplant or death, and certain serious 
adverse events, as well as treatment-related discont inuation. Methods for count data will be used 
for certain safety outcomes to compare treatment differences in number of events, such as number 
of respi[INVESTIGATOR_369331]. 
10.4.[ADDRESS_462389] (DSMB) will review safety and 
administrative data periodically, according to the schedule specified in the DSMB Charter.  Open 
session reports will summarize the following type s of data:  accrual, protocol deviations, data 
completeness, demographics and baseline charact eristics, clinical and laboratory data, adverse 
events and other safety parameters, treatment compliance and dose modifications, reasons for 
treatment discontinuations, and causes of death. The open report will include analyses for all participants combined (i.e., pooled across treatm ent group).  The closed report will present the data 
according to treatment group in a blinded fashion.   
 
The trial is not designed to stop early for effica cy, thus preserving the 5%  probability of a Type I 
error for the final analysis. The DSMB will review sa fety and administrative data to determine the 
safety and feasibility of continuing  the trial.  There exists a possib ility that the DSMB will request 
additional participant-level data and/or recommend  that the study stop temporarily or permanently 
for safety concerns that are set fort h in the DSMB Charter or for admi nistrative reasons such as slow 
accrual. 
 
10.5 MEASURES TO MINIMIZE BIAS 
10.5.1  Randomization and Blinding  
 This is a randomized, double-blind, placebo-controlle d study. Neither site personnel (except for site 
research pharmacist(s) nor the participants will know which study treatment the participant is 
receiving. Pi[INVESTIGATOR_369332]. Pi[INVESTIGATOR_369333]. 
Participants will be randomized at Visit 2 (section 7.2.1) in a 1:1 ratio to receive either pi[INVESTIGATOR_7735] 
2403 mg/d or placebo equivalent using automate d web-based system. All randomization codes will 
be generated by a statistician inde pendent of the trial conduct.   
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 61 of 80  
10.5.2  Unblinding of Treatment Assignment  
The Sponsor (or designee) will prepare the randomi zation list. All subjects, monitors, and study 
center personnel related to the study,  includin g the site pharmacist will be blinded to study 
treatment throughout the study. The randomization schema will be securely maintained 
electronically at the Data Coordinating Center. 
If in the event of an emergency situation when knowledge of the treatmen t assignment will impact 
the clinical management of the subject, the investigator will have the ability to unblind the 
treatment assignment for that subject at any time. If  a subject is unblinded by [CONTACT_093], the 
Sponsor must be informed of the unblinding within [ADDRESS_462390] be determined prior to 
submitting a regulatory safety report for a serious ad verse event (SAE) (as defined in Section 8.2.2).  
Any unblinding event carried out in connection with  submission of a regulatory safety report will be 
conducted by [CONTACT_1034].  
Every reasonable attempt should be made to comple te the early termination study procedures and 
observations (see Appendix A – Schedule of Study Asse ssments) prior to unblinding, as knowledge of 
the treatment arm could influence subject assessment. 
Following study completion, a letter will be sent to all participants to notify them of their assigned 
treatment group. Refer to Appendix D for a draft of the treatment assignment notification letter 
that will be given to the participants.  
 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS 
Every participating clinical site will maintain approp riate medical and research records for this trial, in 
compliance with ICH E6 and regulatory and institutional requirements for the protection of 
confidentiality of participants. Participating clinical  sites will also obtain inst itutional authorization for 
external monitoring by [CONTACT_369392] (and when permitted by 
[CONTACT_1289], to copy) clinical records for th e purposes of quality assurance reviews, audits, and 
evaluation of the study safety, progress, and data validity.  
Source data are defined as all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstr uction and evaluation of the trial. Examples of these 
original documents and data records include, but are no t limited to, hospi[INVESTIGATOR_8735] s, clinical and office 
charts, laboratory notes, memoranda, participant’ s memory aids or evaluation checklists, pharmacy 
dispensing records, recorded audio tapes, recorde d data from automated instruments, copi[INVESTIGATOR_5117], microfiches, photographic negatives, microfilm, x-rays, and participant files an d records kept at the pharmacy, at the laboratories, 
and medico-technical departments involved in the clinic al trial. It is acceptable  to use CRFs as source 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 62 of 80 documents when the data is collected and recorded there as the primary source of information, but 
CRFs will not constitute the only form of so urce document information for this trial. 
12 QUALITY ASSURANCE AND QUALITY CONTROL 
The study will be monitored by [CONTACT_369393] 
(GCP) and to this clinical study protocol according to a Clinical Monitoring Plan. 
The study may be audited by [CONTACT_456]’s clinical quality assurance group to assess compliance with 
GCP (including but not limited to US Food and Drug Administration (FDA) regulations, International 
Conference on Harmonisation (ICH) GCP guidelines, and other applicable regulations). Regulatory 
authorities, the IRB/IEC, and/or the sponsor’s clinical quality assurance group may request access to all 
source documents, eCRFs, and other study documen tation for on-site audits or inspections. Direct 
access to these documents must be  guaranteed by [CONTACT_737] , who must provide support at all 
times for these activities. 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  
13.[ADDRESS_462391]  
This study will be conducted in compliance with GC P as described in FDA regulations (21 CFR parts 50, 
54, 56, and 312) and the ICH document “Guideline for Good Clinical Practice, E6 (R1),” dated [ADDRESS_462392] es stated in the Declaration of Helsinki (version as 
currently endorsed by [CONTACT_369394]). The study will also 
be carried out in keepi[INVESTIGATOR_331522]. 
13.[ADDRESS_462393] be approved by [CONTACT_093]’s 
IRB/IEC before the study is initiated; documentation of this approval (i.e., a copy of the document 
showing IEC/IRB approval including the chairperson’s  signature [CONTACT_67464]) must be 
provided to the sponsors or designee and made avai lable during an inspection by [CONTACT_369395]. 
Other investigator responsibilities regarding IEC/IRB requirements include the following: 
x Submit to the IEC/IRB and to study sponsor or designee for review any advertisements that will 
be used to recruit patients 
x During the conduct of the study, submit progress reports to the IEC/IRB, if required, and request 
x Re-review of the study at least once a year 
x Report, in writing, to the IEC/IRB any SAEs that  occur during the study or  SAEs reported in other 
studies using study treatment, per local IEC/IRB regulations 
x Inform the IEC/IRB of any changes in the prot ocol and obtain documented IEC/IRB approval of 
the changes 
x Provide the IEC/IRB with any other information it requests before or during the conduct of the 
study 
x Maintain a file of study-related information, in cluding all correspondence with the IEC/IRB 
x Provide the IEC/IRB with a final report on the st udy within a time period consistent with local 
requirements 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462394] be approved by [CONTACT_6179]/IRB and sponsor or designee. Th e content of the informed consent 
must comply with FDA regulations (21 CFR 50.25) an d the ICH document “Guideline for Good Clinical 
Practice, E6 (R1),” dated [ADDRESS_462395] dose of the 
study treatment. Before a patient’s participation in the study, the written informed consent form must 
be signed and personally dated by [CONTACT_37410]’s legally acceptable representative, and 
by [CONTACT_28490]. The investigator is responsible for 
keepi[INVESTIGATOR_369334] a secure place. This documen t should not be displayed or made accessible to 
any third party except the study sponsor or designee or regulatory agency representatives. 
If a participant permanently revokes  informed consent and declines fu rther observation and Vital Status 
Assessments, then recordin g of study data will stop. 
13.[ADDRESS_462396] be  maintained include the following: 
1. Copi[INVESTIGATOR_369335] 
2. Signed Principal Investigator [INVESTIGATOR_369336] 
3. Initial Approval letter(s) from and all ot her correspondence to and from the IEC/IRB 
4. Curricula vitae for the Principal Investigator [INVESTIGATOR_34511]-investigators 
5. Documentation of study treatment ship ments from Genentech or designee 
6. Completed and signed dispensing  records for study treatment 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462397] of all study personnel including de legation of authority for all study personnel 
9. Copy of the Investigator Brochure provided at s tart-up and subsequent versions for sites in the 
US. All other sites will maintain their regulatory au thority’s accepted, equivalent product safety 
document (ie. Summary of Product Characteristics (SmPC). 
10. The original signed informed consent forms for each patient screened. Originals of all signed 
consent forms must be retained for all consent amendments for each randomized participant 
11. Copi[INVESTIGATOR_369337] 
12. Copi[INVESTIGATOR_369338], when indicated 
13. Master Patient Log 
14. Copi[INVESTIGATOR_369339] 
 
14.[ADDRESS_462398] ensure that study da ta are accessible to the study sponsors or their 
representatives and to FDA or other regulatory agen cy inspectors. All study-related records (e.g., 
research charts, eCRFs, and other study records) must be retained until disposal is authorized by [CONTACT_369396], which will be no sooner than 2 years af ter approval of the study agent for marketing in 
an ICH region ([LOCATION_002], Europe) and until  there are no pending or contemplated marketing 
applications in an ICH region or [ADDRESS_462399]. These documents may need to be retained for longer periods in some countries due to local regulatory requirements. 
 
14.4 INVESTIGATOR BROCHURE  
The investigator will review the cu rrent version of the Investigator Brochure (IB). Sites outside of the 
U.S. may maintain their regulatory authority’s acce pted, equivalent product safety document (ie. 
Summary of Product Characteristics (S mPC). It is obligatory that the in vestigator be familiar with all 
sections of these documents before initiation of th e study. These documents will be submitted to the 
IEC/IRB. 
14.[ADDRESS_462400] and complete 
electronic case report forms (eCRFs). Data should be recorded via eCRF as soon as possible after 
collection. 
PFT, ECG, and central laboratory data should be reviewed, initialed, and dated by [CONTACT_1961] [INVESTIGATOR_1461]. Completed eCRFs are to be  reviewed by [CONTACT_369397], 
completeness, and legibility within [ADDRESS_462401] unless the forms are incomplete 
because of laboratory data or medical even t follow-up that is not yet available. 
 
 
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462402] udy patient, or which may alter the scope of the 
investigation, the scientific quality of the study, the study design, dosages, duration of therapy, patient assessments (added evaluation that poses potential ri sk or inconvenience to the patient), number of 
patients, and/or patient eligibility criteria, may be  made only after appropriate consultation between 
the investigators, the Study Executive Committee and the DSMB. Individual sites may not alter the 
protocol without advanced consultati on and approval as noted here-in. 
If the consensus is to revise the current protocol, a formal List of Changes will accompany the amended 
protocol and these will initially be submitted to  the DSMB for review and until their recommendations 
for further modification have been addressed or it is approved. Once DSMB approval has been obtained, 
the revised Protocol and the List of Changes will be submitted to the FDA and to the IRBs at all participating clinical sites. Protocol changes will no t be implemented until they have been reviewed and 
approved by [CONTACT_369398] e study participants notified and/or their consent 
re-obtained if indicated by [CONTACT_369399]/or 
responsible IRB. 
 
[ADDRESS_462403] been made to the protocol in response to current COVID-19 pandemic 
recognizing the changes to the risk to participants in the study.  
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 66 of 80 17.1 SAFETY CONCERN AND MANAGEMENT OF STUDY DRUG  
Management and dispensing of study drug 
x When subjects require study drugs, they should be mailed/shipped to the subject’s home after 
completion of the required remote visit or as needed.  
x Primary study outcome measures may need to be deferred based on changes to availability at 
individual sites during the COVID-19 pandemic.  Th e study investigators will address these issues 
by [CONTACT_369400].  
x Missing outcome data, which is a study deviation, should be noted in the site’s study binder as 
due to “COVID-19 Restrictions”. This will fl ag the reason as required for study audits.  
 
17.[ADDRESS_462404] with  patients who are currently enrolled in the study 
through telemedicine and/or videoconferencing. 
 
Schedule of Study Assessments edited for COVID-19. 
x Visits 5 through 11 in the schedule of assessme nts can be converted to phone visits. There may 
be a reduction in the number of assessments, as  not all will be feasible over the phone.  If 
participants cannot be present for the visit, PF Ts or Physical exam cannot be performed. The 
following assessments are categorized as th e “expected assessments”:  Adverse events, 
Concomitant medication review, Supplemental ox ygen review, Study medication dosing, Study 
medication accountability, Weight, Resting O2 Sa turation, Patient questionnaire DAS [ADDRESS_462405] is encouraged to restart study treatment when possible and appropriate.   
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462406] has interru pted study treatment for ≥28 days, a Pre-Restart Visit is required 
(Section 7.2.2). The Pre-Restart Visit will be c onducted on the day study treatment is resumed. 
Subjects who restart study treatment will resume the visit schedule based on their date of 
randomization. If a regularly scheduled visit (W eeks 13, 26, 39, etc.) coincides with the Pre-
Restart Visit, then the elements of the regularl y scheduled visit as outlined above should be 
performed in lieu of the Pre-Restart Visit.  Refer to  Appendix B of the protocol on page 69 for re-
titration. 
x Visit window for visit 11 will be extended to +/- [ADDRESS_462407] been lifted.  
18  LITERATURE REFERENCES  
1. Aletaha, D., T. Neogi, et al. (2010). "2010 Rheuma toid arthritis classification criteria: an American 
College of Rheumatology/European League Against Rheumatism collaborative initiative." Arthritis 
and rheumatism 62(9): 2569-2581. 
2. Allebeck, P., A. Ahlbom, et al. (1981). "Increased mo rtality among persons with rheumatoid arthritis, 
but where RA does not appear on death certificate . Eleven-year follow-up of an epi[INVESTIGATOR_119260]." Scand J Rheumatol 10(4): 301-306. 
3. Bruce, B. and J. F. Fries. (2005). “The Health Assessment Questionnaire (HAQ).” Clin Exp Rheumatol 
23([ADDRESS_462408] 39): S14-8. 
4. Cervantes-Perez, P., A. H. Toro-Perez, et al. (1980). "Pulmonary involvement in rheumatoid 
arthritis." Jama 243(17): 1715-1719. 
5. Cortet, B., T. Perez, et al. (1997). "Pulmonary function tests and high resolution computed 
tomography of the lungs in patients with rheu matoid arthritis." Ann Rheum Dis 56(10): 596-600. 
6. Crapo, R. O. (1994). "Pulmonary-function testing. " The New England journal of medicine 331(1): 25-
30. 
7. Dawson, J. K., H. E. Fewins, et al. (2001). "Fibrosing alveolitis in patients with rheumatoid arthritis as 
assessed by [CONTACT_369401], chest radiography, and pulmonary function 
tests." Thorax 56(8): 622-627. 
8. Doran, M. F., G. R. Pond, et al. (2002). "Trends in incidence and mortality in rheumatoid arthritis in 
[COMPANY_002]ster, Minnesota, over a forty-year p eriod." Arthritis Rheum 46(3): 625-631. 
9. Gabriel, S. E., C. S. Crowson, et al. (1999). "Mor tality in rheumatoid arthritis: have we made an 
impact in 4 decades?" J Rh eumatol 26(12): 2529-2533. 
10. Gochuico, B. R., N. A. Avila, et al. (2008). "Prog ressive preclinical interstitial lung disease in 
rheumatoid arthritis." Arch Intern Med 168(2): 159-166. 
11. Guedes, C., D. Dumont-Fischer, et al. (1999). "Mortal ity in rheumatoid arthritis." Rev Rhum Engl Ed 
66(10): 492-498. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 68 of 80 12. Hochberg, M. C. and T. D. Specto r (1990). "Epi[INVESTIGATOR_261835]: update." Epi[INVESTIGATOR_369340] 12: 247-252. 
13. Isomaki, H. A., O. Mutru, et al. (1975). "Death rate  and causes of death in patients with rheumatoid 
arthritis." Scand J Rheumatol 4(4): 205-208. 
14. Khanna, D., S. Mittoo, et al. (2015). "Connective Ti ssue Disease-associated Interstitial Lung Diseases 
(CTD-ILD) - Report from OMERACT CTD-ILD Wo rking Group." The Journal of rheumatology. 
15. Kim, D. S. (2006). "Interstitial lung disease in rheu matoid arthritis: recent advances." Curr Opin Pulm 
Med 12(5): 346-353. 
16. King, T. E., Jr., W. Z. Bradford, et al. (2014). "A pha se 3 trial of pi[INVESTIGATOR_369341]." The New England journal of medicine  370(22): 2083-2092. 
17. Latsi P.I., du Bois R.M., Nicholson A. G., et al. (2003). " Fibrotic idiop athic interstitial pneumonia: the 
prognostic value of longitudinal functional trends." Am J Resp Crit Care Med 168(5):531-7 
18. Lamblin, C., C. Bergoin, et al. (2001). "Interstitial lung diseases in collagen vascular diseases." Eur 
Respir J Suppl 32: 69s-80s. 
19. Leconte S., D. Ferrant D, et al. (2011) “Validated methods of cough assessment: a systematic review 
of the literature.” Respi[INVESTIGATOR_1516] 81(2): 161-74. 
20. Lee, H. K., D. S. Kim, et al. (2005). "Histopathol ogic pattern and clinical features of rheumatoid 
arthritis-associated interstitial lung  disease." Chest 127(6): 2019-2027. 
21. Lubeck, D. (1994). The economic impa ct of rheumatoid arthritis. Rheumatoid arthritis: Pathogenesis, 
assessment, outcome, and treatment. P. T. Wolf e F. [LOCATION_001], Marcel Dekker, Inc.: 247-259. 
22. McDonagh, J., M. Greaves, et al . (1994). "High resolution computed  tomography of the lungs in 
patients with rheumatoid arthritis and interstiti al lung disease." Br J Rheumatol 33(2): 118-122. 
23. Olson, A. L., J. J. Swigris, et al. "Rheumatoid arth ritis-interstitial lung disease-associated mortality." 
Am J Respir Crit Care Med 183(3): 372-378. 
24. Pi[INVESTIGATOR_35807], T., L. F. Callahan, et al. (1984). "Severe fu nctional declines, work disability, and increased 
mortality in seventy-five rheumatoid arthritis patients studied over nine years." Arthritis Rheum 
27(8): 864-872. 
25. Raghu, G., H. R. Collard, et al. (2011). "An offi cial ATS/ERS/JRS/ALAT statement: idiopathic 
pulmonary fibrosis: evidence-based guidelines fo r diagnosis and management." American journal of 
respi[INVESTIGATOR_4447] 183(6): 788-824. 
26. Sato, T., J. Fujita, et al. (2006). "Non-specific int erstitial pneumonia; as the first clinical presentation 
of various collagen vascular disord ers." Rheumatol Int 26(6): 551-555. 
27. Suzuki, A., Y. Ohosone, et al. (1994). "Cause of death in 81 autopsied patients with rheumatoid 
arthritis." J Rheumatol 21(1): 33-36. 
28. Swigris, J. J., J. Yorke, et al. ( 2010) “Assessing dyspnea and its im pact on patients with connective 
tissue disease-related interstitial lung  disease.” Respir Med 104(9): 1350-5. 
29. van Vollenhoven, R. F. (2009). "Treatment of rheum atoid arthritis: state of the art 2009." Nat Rev 
Rheumatol 5(10): 531-541. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 69 of 80 30. Wallberg-Jonsson, S., M. L. Ohman, et al. (1997). "Cardiovascular morb idity and mortality in patients 
with seropositive rheumatoid arthritis in No rthern Sweden." J Rheu matol 24(3): 445-451. 
31. Wolfe, F., D. M. Mitchell, et al. (1994). "The mortality of rheumatoid arthritis." Arthritis Rheum 
37(4): 481-494. 
32. Yelin, E. (1996). "The costs of rheumatoid arthriti s: absolute, incremental, and marginal estimates." J 
Rheumatol Suppl 44: 47-51. 
33. Yorke J, Moosavi S, Shuldham C, et al. Quantifica tion of dyspnoea using descriptors: Development 
and initial testing of Dyspnoea-12 Thorax. epub 8 December 2009. 
34. Young, A., G. Koduri, et al. (2007). "Mortality in rheumatoid arthritis. Increased in the early course of 
disease, in ischaemic heart disease and in pulmona ry fibrosis." Rheumatology (Oxford) 46(2): 350-
357. 
 
 
  
  
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page [ADDRESS_462409] 
 
Version Date Description Significant Revisions 
  Appendix A - Schedule of Study 
Assessments  
  Appendix B - Capsule Dosing 
Flowchart   
  Appendix C- Safety Reporting 
Definitions and Contacts   
  Appendix D- Treatment Assignment 
Notification Letter  
 
 
 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 71 of 80 Appendix A   SCHEDULE OF STUDY ASSESSMENTS   
 
 
 
   Visit # Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit7 Visit 8 Visit 9 Visit 10 Visit 11 Visit 12
Visit Description Screening PeriodEligibility and 
Random- izationTelephone 
AssessmentTelephone 
AssessmentProtocol Visit Protocol Visit Protocol Visit Lab Assessment Protocol Visit Protocol Visit Protocol VisitEnd of Study Phone 
CallPre-Restart UnscheduledEarly 
Termination
Week # Week -[ADDRESS_462410] 
dose of study drug required if study tx 
was interrupted 
≥28 days13 
Visit Window D-56 to D0 D1 ± 2 days ± 2 days ± 1 week ± 1 week ± 2 weeks ± 1 week ± 2 weeks ± 2 weeks ± 1 week ± 1 week N/A N/A N/A
X
X X7
X X7XXXXXXXXXXXXX
X X7XXXXXXXXX XXX
X X7XXX XXX XXX
X9XXXXX XXX X12XX
X XX X XX X X
X X7XXX XXX XXX
X X7XXX XXX XXX
X X7XXX XXX XXX
X
XX X X X X X X X14X
X
X X X14X
X X7XXX XXX X X14X
X X7XXX X X X
X17X17X
X3XXX X XX X14X
XX XXX XXX XXX
X XX
X XX X X
X XX X X
X XX X X X
X XX X X X
X XX X X X
X XX X X X
X XXSupplemental Oxygen ReviewStudy  Assessments
Informed C onsent
M edic al Histor y  / Rev iew of Sy stems
Adv erse Ev ent Assessment
Concomitant Med Review
DNA Paxgene17Study Medication Dosing
Study  M edication Accountability
P hy sical Ex am
Vital Signs (heart rate and blood pressure)
Weight
Height
Lab Assessments1
Liver Function Testing Only11
Serologic tests10
Pregnancy Test (blood)2
Biomarkers16 (plasma, serum, and RNA)
ECG
Resting Oxygen Saturation
Patient Questionnaires
DAS 28 GH VAS
Pa ti ent GA
P hy sician GA
SGRQ
HAQ20
Dyspnea-12 
Leicester Cough Questionnaire
RAPID3 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369220]-ILD Version 8.0 
Protocol # TRAIL1 13OCT2020 
Page 72 of 80 X XX
X
X4X X18
X5X7, 8X8X8X8X8X8
X6XX
X7
X
X X X
10 Serologic tests include: Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), C-Reactive Protein (CRP), and Cyclic Ci tr ullinated P eptide (C C P )
16RNA biomar ker  will only  be collected at Visit 2(week 0) and Visit 11 (week 52) or  Ear ly  Ter m
[ADDRESS_462411] 3 months will be acceptableJoint Count 
5FVC, FEV1 before and after bronchodilator administration Tr ansbr onchial biopsy  or  SLB (if av ail)[ADDRESS_462412] scan
Spi[INVESTIGATOR_369342] s , DLCO or TLCO  
C onfir mation of Eligibility
Randomization
Vital Status Assessment
1 Lab Assessments include • Hematology (complete blood count with platelet count and automated differential) • Serum chemistry pr ofile (albumin, alkaline phosphatase, ALT/SGP T, AST/SGOT, total bilir ubin, calcium,  cr eatinine, glomer ular  filtr ation r ate (eG RF), gamma-glutamyl transferase 
[GGT], glucose, potassium, sodium, BUN, uric acid and amylase)
[ADDRESS_462413] on re-ti tra ti on of dos e
13P ar ticipants who r estar t study  tr eatment will r esume the v isit schedule based on their  date of r andomization. If a r egular ly  sc heduled visit (Weeks 13, 26, 39, etc.) coincides with the Pre-Restart Visit, then all of the elements of the regularly schedule d visit should be performed in lieu of the 
14The elements of the v isit are up to the discretion of the inv estigator. 
15Surgical lung biopsy (SLB) or transbronchial biopsy, if performed, may be obtained up to [ADDRESS_462414] participant on dose titration and diary usage; 1st dose must  be taken in clinic on day of randomization
11Liv er  Function Testing Only  includes:  AST, ALT, bilir ubin, and alkaline phosphatase
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369343]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 73of 80Appendix B TRAIL1 CAPSULE DOSING FLOWCHART
Dose reduction, interruption, and discontinuation of study drug to manage adverse events will be at the 
Investigators discretion. Subjects may be re-titr ated over [ADDRESS_462415] subsided. 
The below flow chart is provided as guidance for re -titration. The medical monitor is also available to 
discuss dose titration and management of adverse events. 

TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369343]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 74of 80Appendix C SAFETY REPORTIN G DEFINITIONS AND CONTACTS
The definitions below are based on the Internation al Conference on Harmonization (ICH) guidelines 
and Food and Drug Administration (FDA) regulations. The use of italic font in this section refers to 
definitions taken from ICH guidelines and/or FD A regulations. Other definitions relate to company 
specific glossaries. 
xAdverse Drug Reaction (ADR)
In the pre-approval clinical experience or in other clinical trial experiences:
Any noxious and unintended response to a medicinal product related to any dose will be considered 
an ADR.
The phrase "responses to a medicinal product" or "associated with the use of the medication," means 
that a causal relationship between a medicinal produc t and an adverse event is at least a reasonable 
possibility, i.e., the relationship cannot be ruled out.
xAdverse Event (AE)
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product and which does not necessarily  have to have a causal relationship with this 
treatment. An AE can therefore be any unfavora ble and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or di sease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product.
xAwareness Date
The date any Party (including employees of affiliates or agents acting on behalf of either Party), first 
has knowledge of the minimum data elements as defi ned by [CONTACT_12212] E2A guideline. At the very least, the 
following data must be provided fo r a case to be considered as valid:
xan identifiable reporter*
xan identifiable patient**(i.e., either CRF number,  patient/subject number, initials, gender, date 
of birth, age or age group 
xa drug / counterfeit drug
xan adverse event (or pregnancy)
*For AE reports from social media sources, verified contact [CONTACT_8972] (e.g., email address) are considered 
an identifiable reporter.
**For reports from healthcare professionals, “a patient”  is considered an identifiable patient criterion. 
The minimum data elements should be obtained initia lly prior to transmitting the information to the 
other Party. In the event that an AE/ADR or pregna ncy report is lacking mini mum data elements, this 
report should not be forwarded to the other Party until all the minimum d ata elements are gathered. 
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369343]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 75of 80The originating Party will ensure prompt follow-up as necessary.
xClinical Trial/ Study
Any investigation in human subjects intended to disc over or verify the clinical, pharmacological and/or 
other pharmacodynamic effects of  one or more investigational medicinal product(s), and/or to 
identify any adverse reactions to one or more investigational medicinal product(s), and/or to study 
absorption, distribution, metabolism and excretion of  one or more investigational product(s) with the 
object of ascertaining their safety and/or efficacy.
xDevelopment Safety Update Report (DSUR) 
A comprehensive, thoughtful annual review and evalu ation of pertinent safety information collected 
during the reporting period related to a drug und er investigation, whether ma rketed or not. The main 
objective of a DSUR is:
xAssess whether the information ob tained by [CONTACT_369402]/development program and study 
results.
xEuropean Medicines Agency (EMA)
The centralized European regulatory authority for the European Union (EU) member states.
xEuropean Economic Area (EEA)
European Union (EU) plus Iceland, Liechtenstein and Norway.
xExpedited Safety Report
A single case report requiring submission to any re gulatory authority within 7 and/or 15 calendar days.
xFood and Drug Administration  (FDA)
US Federal Agency charged with the responsibility of enforcing the Federal Food, Drug and Cosmetic 
Laws and Regulations.
xInternational conference on Harmonization (ICH)
International Conference on Harmonization of Technical Requirements for Registration on 
Pharmaceuticals for Human Use.
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369343]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 76of 80xInvestigational Medi cinal Product (IMP)
A pharmaceutical form of an active substance or placebo being tested or used as a reference in a 
clinical trial, including products already with  a marketing authorization but used or assembled 
(formulated or packaged) in a way different from the authorized form, or when used for an 
unauthorized indication, or when used to gain further information about the authorized form.
xNon-Serious Adverse Event
Any event that does not meet the definition of serious as defined below under SAE/SADR.
xProduct
The [COMPANY_002] product that is the su bject of the trial/study as defi ned in the corresponding agreement.
xReference safety information (RSI)
Depending on the development and marketing status of the drug, the Reference Safety Information 
(RSI) may be one or more of the following:
xCore Data Sheet (CDS)
xSummary of Product Ch aracteristics (SPC)
xInvestigator’s Brochure 
xInternational Standard Prescribing Information (ISPI)
xLocal Label, e.g., [LOCATION_002] Package Insert (USPI)
xSerious Adverse Event (SAE) or S erious Adverse Drug Reaction (SADR)
A serious adverse event (experience) or reaction is an y untoward medical occurrence or effect that at 
any dose:
xresults in death
xis life-threatening
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369343]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 77of 80Note: The term "life-threatening" refers to an event in which the patient was at risk of death at the 
time of the event; it does not refer  to an event that hypothetically might have caused death if it were 
more severe.
xrequires inpatient hospi[INVESTIGATOR_369344]/incapacity 
xis a congenital anomaly/birth defect
xis an important medical event (an event that jeopa rdizes the patient or may require intervention 
to prevent one of the othe r outcomes listed above).
Examples of such events are intensive treatmen t in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that  do not result in hospi[INVESTIGATOR_059]; or development 
of drug dependency or drug abuse.
Any suspected transmission via a me dicinal product of an infectious agent is also considered a serious 
adverse reaction.
In certain protocols, specific arrangements may be made for SAE reporting (e.g., efficacy end points, 
study, specific events) which are not reported as SAEs  to regulatory authorities during a clinical trial. 
Details of these should be document ed and made known to either Party.
xSingle case reports
A document providing the most complete information related to an individual case at a certain point 
of time. An individual case is the information provided  by a primary source to describe adverse events 
following the administration of one or more medicinal products to an individual patient at a particular 
point of time.
xSix Monthly S[LOCATION_003]R Report
S[LOCATION_003]R report for an Investigational Medicinal Product  (IMP) containing a listing of all S[LOCATION_003]Rs for a 
defined six monthly period providing a brief summary of any safety-related issues for that IMP. 
xSponsor
ICH E6:
An individual, company, institution, or organiza tion which takes responsibility for the initiation, 
management, and/or financing of a clinical trial.
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369343]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 78of 80CFR 312.3:
A person who takes responsibility for and initiates a clinical investigation. The Sponsor may be an 
individual or pharmaceutical company, governmental agency, academic institution, private 
organization, or other organization.
xS[LOCATION_003]R
Suspected Unexpected Serious Adverse Reaction.
xUnexpected Adverse Drug Reaction
An adverse reaction, the nature or severity of wh ich is not consistent with the applicable product 
information (e.g., Investigator's Brochure for an unapproved Investigational Medicinal Product or 
package insert/summary of product charact eristics for a marketed medicinal product).
[COMPANY_002] Contacts
Activity Person Responsible
General Queries/  Aggregate 
Reports (e.g., DSUR, Line-
listings of Non -serious AEs)Drug Safety Contact [CONTACT_369403]: 
[EMAIL_7095]
Single Case Management Single case reports to [COMPANY_002]: 
Central Operations Mailbox: [EMAIL_7096]
Fax (Clinical): [PHONE_7625]/ 373 779/ 373 793/ 390 959
Fax (Spontaneous): [PHONE_7626]Queries on Single Case Reports
/Case Transmission Verification:
Safety Operations Contact [CONTACT_369403]: 
[EMAIL_7097]
Cc:
Ivan O. Rosas
Study Principal Investigator
[CONTACT_363614] [ADDRESS_462416]
Houston, TX [ZIP_CODE] For US IIS only:
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369343]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 79of 80BCM Contacts
Activity Person Responsible
Single Case Management, 
Safety Crisis Management, 
Aggregate Safety ReportsIvan O. Rosas
Pulmonary Critical Care and Sleep Medicine
Baylor College of Medicine7200 Cambridge Street
Houston, TX [ZIP_CODE]
Tel: (713)-798-8842Fax: ([PHONE_7620]
[EMAIL_7092]
TRAIL1: A Phase ll Study of Pi[INVESTIGATOR_369343]-ILD Version 8.0
Protocol # TRAIL1 13OCT2020
Page 80of 80
Appendix D TREATMENT ASSIGNMENT NOTIFICATION LETTER
              __/__/__
Dear (participant name),
Thanks to the hard work and commitment of the investigators, coordinators and, study participants like 
you, the TRAIL1 study has been successfully comp leted. Not only did your participation contribute 
important information for testing a new treatment, but it  will also continue to help us learn more about 
Rheumatoid Arthritis Interstitial Lung Disease as we perform additional analyses of the data and samples 
collected during the TRAIL1 study. 
We want to take this opportunity to tell you whether you were taking Pi[INVESTIGATOR_369345]1 study. Through the randomization process, your drug assignment was __ Pi[INVESTIGATOR_369346] 
___.
We will post the publications related to TRAIL1 study  that describes the study results on the TRAIL1 
website once it is published. 
Once again, we would like to convey our sincere app reciation for your participation. We cannot thank 
you enough for all the time you have put into this study. We truly could not have done this without you!
Please let us know if you have any questions. 
With warmest wishes and great gratitude,
(Signatures)
________________